,Label,Smiles,drug_name,drug_type
0,negative,CC(C)(OC1=CC=C(C=C1)[C@H]2CC2(Cl)Cl)C(O)=O,Ciprofibrate,4A11-Inducer
1,negative,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Dexamethasone,4A11-Inducer
2,negative,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F,Lansoprazole,4A11-Inducer
3,negative,[Hg],"Mercury, Metallic",4A11-Inhibitor
4,negative,CC[C@@]1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Phenobarbital,4A11-Inducer
5,negative,CCCC(CCC)C(O)=O,Valproic Acid,4A11-Inducer
6,negative,CO[C@@]12CC[C@]3(C[C@H]1[C@](C)(O)C(C)(C)C)[C@@H]4CC5=CC=C(O)C6=C5[C@]3(CCN4C[C@@H]7CC7)[C@@H]2O6,Buprenorphine,CP2CI-Substrate
7,negative,CN1C(=O)CC(=O)N(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3,Clobazam,CP2CI-Substrate
8,negative,CCC1=CC2=C(S1)N(C)C(=O)CN=C2C3=C(Cl)C=CC=C3,Clotiazepam,CP2CI-Substrate
9,negative,ClCCN(CCCl)[P@]1(=O)NCCCO1,Cyclophosphamide,CP2CI-Substrate
10,negative,NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(N)C=C2,Dapsone,CP2CI-Substrate
11,negative,OC(CN1C=NC=N1)(CN2C=NC=N2)C3=C(F)C=C(F)C=C3,Fluconazole,CP2CI-Inhibitor
12,negative,ClCCN[P@@]1(=O)OCCCN1CCCl,Ifosfamide,CP2CI-Substrate
13,negative,CC[C@]1(NC(=O)N(C)C1=O)C2=CC=CC=C2,Mephenytoin,CP2CI-Substrate
14,negative,O=C1NC(=O)[C@](N1)(C2=CC=CC=C2)C3=CC=CC=C3,Phenytoin,CP2CI-Substrate
15,negative,O=C1CC[C@@H](N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,Thalidomide,CP2CI-Substrate
16,negative,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,Tolbutamide,CP2CI-Substrate
17,negative,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1OC(C)=O)O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]4(CO4)C(=O)[C@H](C)[C@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C,Troleandomycin,CP2CI-Inhibitor
18,negative,C[C@]12CCC(=O)C=C1CC[C@H]3[C@@H]4CC[C@H](C(=O)CO)[C@]4(C[C@H](O)[C@H]23)C=O,Aldosterone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer
19,negative,CC[C@]1(CCC(=O)NC1=O)C2=CC=C(N)C=C2,Aminogluthetimide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor
20,negative,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,Androstanolone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Substrate
21,negative,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC4=CC=CC=C4)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CN=CN5)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC6=CC=C(O)C=C6)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC7=CC=C(O)C=C7)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC8=CC=C(O)C=C8)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC9=CC=CC=C9)C(=O)N[C@@H](CC%10=CC=CC=C%10)C(=O)N[C@@H](CC%11=CC=C(O)C=C%11)C(=O)N[C@@H]([C@@H](C)O)C(=O)N%12CCC[C@H]%12C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC,Insulin (human),Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer
22,negative,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1,Metoclopramide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor
23,negative,OP([O-])([O-])=O,[32P]Natriumphosphat,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Substrate
24,negative,CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O,Cefmetazole,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
25,negative,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C5=CC=C(O)C=C5)C(=O)C1=O,Cefoperazone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
26,negative,CON=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(O)=NN3C)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4,Ceftriaxone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
27,negative,CC(C)[C@@H]1NC(=O)[C@H](NC(=O)C2=C3N=C4C(OC3=C(C)C=C2)=C(C)C(=O)C(N)=C4C(=O)N[C@@H]5[C@H](C)OC(=O)[C@@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)[C@H](C)OC(=O)[C@@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]7CCCN7C1=O,Dactinomycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor
28,negative,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](O)C3=O)C5(C)C,Docetaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor
29,negative,CC(C)N1C2=C(C=CC=C2)C(C3=CC=C(F)C=C3)=C1C=C[C@H](O)C[C@H](O)CC(O)=O,Fluvastatin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
30,negative,NC(=O)NO,Hydroxycarbamide,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
31,negative,CN(CC1=NC2=C(N=C1)N=C(N)N=C2N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,Methotrexate,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
32,negative,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C3=C(O)C=CC(O)=C3C2=O,Mitoxantrone,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor
33,negative,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7)C(C)=C1C5(C)C,Paclitaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
34,negative,CC[C@H](C)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CO)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN)[C@H](C)CC)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC4=CNC5=C4C=CC=C5)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC6=CC=CC=C6)C(N)=O)C7=CC=C(OS(O)(=O)=O)C=C7,Pancreozymin (cholecystokinin),Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
35,negative,OC1=C(C=C(C=C1)[C@@]2(OC(=O)C3=C(Br)C(Br)=C(Br)C(Br)=C23)C4=CC(=C(O)C=C4)S(O)(=O)=O)S(O)(=O)=O,Sulfobromophthalein,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
36,negative,CC1=C(Br)C(C)=C(NC(=O)CN(CC(O)=O)CC(O)=O)C(C)=C1,Technetium (99mTc) Mebrofenin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
37,negative,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Testosterone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate
38,negative,CC(C)(C#N)C1=CC(CN2C=NC=N2)=CC(=C1)C(C)(C)C#N,Anastrozole,19A-Inhibitor
39,negative,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Betamethason,19A-Inducer
40,negative,C1=CC=C(C=C1)[C@H](N2C=CN=C2)C3=CC=C(C=C3)C4=CC=CC=C4,Bifonazole,19A-Inhibitor
41,negative,CCCC(=O)NC1=C2N=CN([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3OC(=O)CCC)C2=NC=N1,Bucladesine,19A-Inducer
42,negative,CCNC(=O)[C@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C34)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H]6CCC(=O)N6,Buserelin,19A-Inducer
43,negative,ClC1=CC=C(C=C1)C(C2=CC=C(Cl)C=C2)C(Cl)(Cl)Cl,Clofenotane,19A-Inhibitor
44,negative,CCN(CC)CCOC1=CC=C(C=C1)C(=C(/Cl)C2=CC=CC=C2)C3=CC=CC=C3,Clomifene,19A-Inhibitor
45,negative,ClC1=CC=CC(Cl)=C1NC2=NCCN2,Clonidine,19A-Inducer
46,negative,ClC1=C(C=CC=C1)C(N2C=CN=C2)(C3=CC=CC=C3)C4=CC=CC=C4,Clotrimazole,19A-Inhibitor
47,negative,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C,Cyproterone,19A-Inhibitor
48,negative,C[C@]12CC3=C(ON=C3)C=C1CC[C@@H]4[C@@H]2CC[C@@]5(C)[C@H]4CC[C@@]5(O)C#C,Danazol,19A-Inhibitor
49,negative,CCCCOC(=O)C1=C(C=CC=C1)C(=O)OCCCC,Dibutylphthalate,19A-Inducer
50,negative,CCC(C1=CC=C(O)C=C1)=C(CC)C2=CC=C(O)C=C2,Diethylstilbestrol,19A-Inducer
51,negative,ClC1=CC=C(CO[C@@H](C[C@H]2C=NC=N2)C3=C(Cl)C=C(Cl)C=C3)C=C1,Econazole,19A-Inhibitor
52,negative,CCOC(=O)C1=CN=CN1[C@@H](C)C2=CC=CC=C2,Etomidate,19A-Inhibitor
53,negative,CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C,Etretinate,19A-Inhibitor
54,negative,C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O,Exemestane,19A-Inhibitor
55,negative,C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@]34C)[C@@H]1CCC2=O,Formestane,19A-Inhibitor
56,negative,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,Glutathione,19A-Inducer
57,negative,ClC1=CC(Cl)=C(C=C1)[C@H](CN2C=CN=C2)OCC3=C(Cl)C=CC=C3Cl,Isoconazole,19A-Inhibitor
58,negative,CC(C)NC[C@H](O)C1=CC(O)=C(O)C=C1,Isoprenaline,19A-Inducer
59,negative,CC[C@H](C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@H]5CO[C@@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4,Itraconazole,19A-Inhibitor
60,negative,N#CC1=CC=C(C=C1)C(N2C=NC=N2)C3=CC=C(C=C3)C#N,Letrozole,19A-Inhibitor
61,negative,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Levacetylmethadol,19A-Substrate
62,negative,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Levonorgestrel,19A-Inhibitor
63,negative,O[C@H]([C@H]1CCCCN1)C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F,Mefloquine,19A-Inhibitor
64,negative,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Methyltestosterone,19A-Inducer
65,negative,ClC1=CC=C(CO[C@H](CN2C=CN=C2)C3=CC=C(Cl)C=C3Cl)C(Cl)=C1,Miconazole,19A-Inhibitor
66,negative,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O,Nandrolone,19A-Substrate
67,negative,NC[C@@H](O)C1=CC(O)=C(O)C=C1,Norepinephrine,19A-Inhibitor
68,negative,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,Oxycodone,19A-Inhibitor
69,negative,CNC[C@H](O)C1=CC(O)=CC=C1,Phenylephrine,19A-Inducer
70,negative,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Prasterone,19A-Substrate
71,negative,OC1=CC=C(C=C1)C2=C(C(=O)C3=CC=C(OCCN4CCCCC4)C=C3)C5=CC=C(O)C=C5S2,Raloxifene,19A-Inhibitor
72,negative,CCC(C1=CC=CC=C1)=C(/C2=CC=CC=C2)C3=CC=C(OCCN(C)C)C=C3,Tamoxifen,19A-Inhibitor
73,negative,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13,Tibolone,19A-Inhibitor
74,negative,CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O,Tinidazole,19A-Inhibitor
75,negative,ClC1=CC(Cl)=C(C=C1)[C@@H](CN2C=CN=C2)OCC3=C(Cl)SC=C3,Tioconazole,19A-Inhibitor
76,negative,NCC=C,Trastuzumab,19A-Inhibitor
77,negative,CC1=C(C)C2=C(CC[C@](C)(COC3=CC=C(C[C@@H]4SC(=O)NC4=O)C=C3)O2)C(C)=C1O,Troglitazone,19A-Inhibitor
78,negative,CN1N=NC2=C1C=C(C=C2)[C@@H](N3C=NC=N3)C4=CC=C(Cl)C=C4,Vorozole,19A-Inhibitor
79,negative,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C(O)N=CN=C23,Inosine,Solute_carrier_family_28_member_3-Inhibitor
80,negative,S=C1NC=NC2=C1NC=N2,Mercaptopurine,Solute_carrier_family_28_member_3-Substrate
81,negative,NC(=O)C1=NN(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,Ribavirin,Solute_carrier_family_28_member_3-Substrate
82,negative,NC1=NC2=C(N=CN2)C(=S)N1,Tioguanine,Solute_carrier_family_28_member_3-Substrate
83,negative,CC1=C(C=CC(C)=CC=CC(C)=CC(O)=O)C(C)(C)CCC1,Tretinoin,Solute_carrier_family_28_member_3-Inducer
84,negative,N[Pt](N)(Cl)Cl,Cisplatin,Probable_low_affinity_copper_uptake_protein_2-Substrate
85,negative,[Ag],Silver,Probable_low_affinity_copper_uptake_protein_2-Inhibitor
86,negative,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C2=O)C(O)=O,Cefalexin,Multidrug_and_toxin_extrusion_protein_1-Substrate
87,negative,CCN(CC)CCC[C@@H](C)NC1=CC=NC2=C1C=CC(Cl)=C2,Chloroquine,Multidrug_and_toxin_extrusion_protein_1-Inhibitor
88,negative,COC1=C(OC[C@H]2CNC(=O)O2)C=CC=C1,Mephenoxalone,Multidrug_and_toxin_extrusion_protein_1-Substrate
89,negative,CN(C)C(=N)NC(N)=N,Metformin,Multidrug_and_toxin_extrusion_protein_1-Substrate
90,negative,COC1=CC(CC2=C(N)N=C(N)N=C2)=CC(OC)=C1OC,Trimethoprim,Multidrug_and_toxin_extrusion_protein_1-Inhibitor
91,negative,C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]2CO)O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]4C=C(CO)[C@@H](O)[C@H](O)[C@H]4O,Acarbose,2E1-Inducer
92,negative,CC(O)=O,Acetic Acid,2E1-Substrate
93,negative,C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C(N)N=CN=C23,Ademetionine,2E1-Inhibitor
94,negative,OC1=NC=NC2=C1C=NN2,Allopurinol,2E1-Inhibitor
95,negative,CCOC(=O)C1=CC=C(N)C=C1,Benzocaine,2E1-Inhibitor
96,negative,CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C2=CC=CC=N2,Brompheniramine,2E1-Substrate
97,negative,NC(N)=O,Carbamide,2E1-Inducer
98,negative,CN(C)CCO[C@@H](C1=CC=C(Cl)C=C1)C2=NC=CC=C2,Carbinoxamine,2E1-Substrate
99,negative,ClC(Cl)Cl,Chloroform,2E1-Substrate
100,negative,CC1=CC(O)=CC(C)=C1Cl,Chloroxylenol,2E1-Substrate
101,negative,CNC(NCCSCC1=C(C)NC=N1)=N/C#N,Cimetidine,2E1-Inhibitor
102,negative,OC(=O)C1=CN([C@H]2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O,Ciprofloxacin,2E1-Inducer
103,negative,CN(C)CCC[C@@]1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3,Citalopram,2E1-Substrate
104,negative,CC1=C(CCCl)SC=N1,Clomethiazole,2E1-Inhibitor
105,negative,COC1=CC=C2C(=CC1=O)[C@H](CCC3=CC(OC)=C(OC)C(OC)=C23)NC(C)=O,Colchicine,2E1-Inducer
106,negative,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1,Dextromethorphan,2E1-Substrate
107,negative,CCOCC,Diethyl Ether,2E1-Inducer
108,negative,CCN[C@@H]1C[C@@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,Dorzolamide,2E1-Substrate
109,negative,FC(F)OC(F)(F)[C@H](F)Cl,Enflurane,2E1-Substrate
110,negative,CCN(CC)C(=O)C(=CC1=CC(=C(O)C(O)=C1)[N+]([O-])=O)C#N,Entacapone,2E1-Inhibitor
111,negative,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1,Eszopiclone,2E1-Substrate
112,negative,CC[C@]1(C)CC(=O)NC1=O,Ethosuximide,2E1-Substrate
113,negative,CC1=NC=C(C=C1)C2=C(C=C(Cl)C=N2)C3=CC=C(C=C3)S(C)(=O)=O,Etoricoxib,2E1-Inhibitor
114,negative,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,Felbamate,2E1-Substrate
115,negative,OC(=O)C1=CC=CC=C1NC2=CC=CC(=C2)C(F)(F)F,Flufenamic Acid,2E1-Inducer
116,negative,C[C@@H]1CCC2=CC(F)=CC3=C2N1C=C(C(O)=O)C3=O,Flumequine,2E1-Inhibitor
117,negative,OCCN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1,Fluphenazine,2E1-Inhibitor
118,negative,CCN(CC)CCN1C(=O)CN=C(C2=C(F)C=CC=C2)C3=C1C=CC(Cl)=C3,Flurazepam,2E1-Inhibitor
119,negative,NC1=NC(=O)C2=C(N1)N=CC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=N2,Folic Acid,2E1-Substrate
120,negative,CC1=CNN=C1,Fomepizole,2E1-Inhibitor
121,negative,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl,Furosemide,2E1-Substrate
122,negative,N[C@@H]1[C@@H](O)O[C@@H](CO)[C@H](O)[C@H]1O,Glucosamine,2E1-Substrate
123,negative,OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,Glucose,2E1-Inhibitor
124,negative,OCC(O)CO,Glycerol,2E1-Inducer
125,negative,FC(F)(F)[C@@H](Cl)Br,Halothane,2E1-Substrate
126,negative,NCCC1=CNC=N1,Histamine,2E1-Inducer
127,negative,FC(F)O[C@@H](Cl)C(F)(F)F,Isoflurane,2E1-Substrate
128,negative,NNC(=O)C1=CC=NC=C1,Isoniazid,2E1-Inducer
129,negative,CC(C)O,Isopropanol,2E1-Inducer
130,negative,[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O,Isosorbide Dinitrate,2E1-Inhibitor
131,negative,CC(=O)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=CN=C4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2,Ketoconazole,2E1-Inhibitor
132,negative,C[N+](C)(C)C[C@H](O)CC([O-])=O,Levocarnitine,2E1-Substrate
133,negative,COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1,Levomepromazine,2E1-Inhibitor
134,negative,CN1CCN=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3,Medazepam,2E1-Inhibitor
135,negative,C[C@H]1C[C@@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@@H](O)[C@H]2[C@@]4(C)CCC(=O)C=C14,Medrysone,2E1-Inhibitor
136,negative,CCCC(C)(COC(N)=O)COC(N)=O,Meprobamate,2E1-Substrate
137,negative,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O,Methazolamide,2E1-Inhibitor
138,negative,CC(C)(C1=CC=CN=C1)C(=O)C2=CC=CN=C2,Metyrapone,2E1-Inhibitor
139,negative,CN([C@H]1CCN(CC1)C2=NC3=C(C=CC=C3)N2CC4=CC=C(F)C=C4)C5=NC=CC(=O)N5,Mizolastine,2E1-Inhibitor
140,negative,CCCCCCCCC=CCCCCCCCC(O)=O,Monoethanolamine Oleate,2E1-Substrate
141,negative,COC(=O)C1=C(C)NC(C)=C([C@@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCN(C)CC3=CC=CC=C3,Nicardipine,2E1-Substrate
142,negative,NC(=O)C1=CC=CN=C1,Nicotinamide,2E1-Inhibitor
143,negative,COC(=O)C1=C(C)NC(C)=C([C@H]1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OC,Nifedipine,2E1-Inhibitor
144,negative,COC(=O)C1=C(NC(C)=C([C@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC(C)C)C#N,Nilvadipine,2E1-Substrate
145,negative,CN(CC#C)CC1=CC=CC=C1,Pargyline,2E1-Inhibitor
146,negative,OC1=CC=CC=C1,Phenol,2E1-Substrate
147,negative,CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C,Pilocarpine,2E1-Substrate
148,negative,COC1=CC2=C(C=CN=C2C=C1)[C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4C=C,Quinidine,2E1-Substrate
149,negative,OC(=O)C1=C(O)C=CC=C1,Salicylic Acid,2E1-Inducer
150,negative,FCOC(C(F)(F)F)C(F)(F)F,Sevoflurane,2E1-Substrate
151,negative,CCCC1=NN(C)C2=C1N=C(NC2=O)C3=C(OCC)C=CC(=C3)S(=O)(=O)N4CCN(C)CC4,Sildenafil,2E1-Inhibitor
152,negative,[Na+].[Cl-],Sodium Chloride,2E1-Inducer
153,negative,CO[C@@H](CNC(=O)C1=C(OCC([O-])=O)C=CC=C1)C[Hg]O,Sodium Salicylate,2E1-Inducer
154,negative,CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,Streptozocin,2E1-Inducer
155,negative,ClC1=CC=C(CS[C@H](CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C=C1,Sulconazole,2E1-Inhibitor
156,negative,NC1=CC=C(C=C1)S(=O)(=O)NC2=NC=CC=N2,Sulfadiazine,2E1-Substrate
157,negative,NC1=CC=C(C=C1)S(N)(=O)=O,Sulfanilamide,2E1-Inhibitor
158,negative,CCCCCNC(=N)NN=CC1=CNC2=C1C=C(CO)C=C2,Tegaserod,2E1-Inhibitor
159,negative,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C,Tenofovir Disoproxil,2E1-Inhibitor
160,negative,CN1C=CNC1=S,Thiamazole,2E1-Inhibitor
161,negative,CCC[C@@H](C)[C@]1(CC)C(=O)NC(S)=NC1=O,Thiopental,2E1-Inhibitor
162,negative,[O-]S([S-])(=O)=O,Thiosulfate,2E1-Inhibitor
163,negative,CN(C)C(=S)SSC(=S)N(C)C,Thiram,2E1-Substrate
164,negative,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1,Ticlopidine,2E1-Inhibitor
165,negative,C[C@H](S)C(=O)NCC(O)=O,Tiopronin,2E1-Inhibitor
166,negative,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2,Tocopherol (vit E),2E1-Inhibitor
167,negative,COC1=C(O)C=C2CCN[C@]3(CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=CC(C)=C(OC)C(O)=C67)[C@H](O)N5[C@@H](COC3=O)C8=C4C(OC(C)=O)=C(C)C9=C8OCO9)C2=C1,Trabectedin,2E1-Substrate
168,negative,N[C@H]1C[C@@H]1C2=CC=CC=C2,Tranylcypromine,2E1-Inhibitor
169,negative,CN1C(=O)OC(C)(C)C1=O,Trimethadione,2E1-Substrate
170,negative,OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N@@]23CCCC3)(C4=CC=CC=C4)C5=CC=CC=C5,Trospium,2E1-Inhibitor
171,negative,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Ursodeoxycholic Acid,2E1-Inducer
172,negative,OCC(CO)N[C@H]1C[C@@](O)(CO)[C@H](O)[C@@H](O)[C@@H]1O,Voglibose,2E1-Inducer
173,negative,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)O[C@H]4CCCC4)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C5=CC=CC=C5C,Zafirlukast,2E1-Inhibitor
174,negative,CN1CCN(CC1)C(=O)O[C@H]2N(C(=O)C3=NC=CN=C23)C4=CC=C(Cl)C=N4,Zopiclone,2E1-Substrate
175,negative,CC(=O)OC1=C(C=CC=C1)C(O)=O,Acetylsalicylic Acid,GST-Inducer
176,negative,COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(=O)CO)C(O)=C3C2=O,Adriamycin,GST-Substrate
177,negative,CC(C)CCON=O,Amyl Nitrite,GST-Substrate
178,negative,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,Artemisinin,GST-Inhibitor
179,negative,OC[C@H](O)[C@H]1OC(=O)C(O)=C1O,Ascorbic Acid (vit C),GST-Inhibitor
180,negative,CC1=C(C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC2=C(C)CCCC2(C)C)C(C)(C)CCC1,Betacarotene,GST-Inducer
181,negative,CS(=O)(=O)OCCCCOS(C)(=O)=O,Busulfan,GST-Substrate
182,negative,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2,Camphora,GST-Inducer
183,negative,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Chenodeoxycholic Acid,GST-Inhibitor
184,negative,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl,Chlorambucil,GST-Inducer
185,negative,COC(=O)[C@H]1[C@H](C[C@H]2CC[C@@H]1N2C)OC(=O)C3=CC=CC=C3,Cocaine,GST-Inducer
186,negative,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC4=C1C=CC=C4,Dicoumarol,GST-Inhibitor
187,negative,CCN(CC)C(=O)N1CCN(C)CC1,Diethylcarbamazine,GST-Inducer
188,negative,CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl,Etacrynic Acid,GST-Substrate
189,negative,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,Finasteride,GST-Inhibitor
190,negative,C[C@H]1O[C@@H]1P(O)(O)=O,Fosfomycin,GST-Substrate
191,negative,NC[C@@]1(CCCCC1)CC(O)=O,Gabapentin,GST-Inducer
192,negative,CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CN=CN7)N,Glucagon,GST-Inhibitor
193,negative,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O,Glyceryl Trinitrate,GST-Inducer
194,negative,NCC(O)=O,Glycine,GST-Inducer
195,negative,O[Fe++].CC1=C(CCC(O)=O)C2=CC3=NC(=CC4=C(C=C)C(C)=C([N-]4)C=C5N=C(C=C1[N-]2)C(C)=C5C=C)C(C)=C3CCC(O)=O,Hematin,GST-Inhibitor
196,negative,C[C@]12CCC(=O)C=C1CC[C@H]3[C@@H]4CC[C@](O)(C(=O)CO)[C@@]4(C)C[C@H](O)[C@H]23,Hydrocortisone,GST-Inducer
197,negative,OO,Hydrogen Peroxide,GST-Inhibitor
198,negative,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O,Ibuprofen,GST-Inducer
199,negative,COC1=CC2=C(C=C1)N(C(C)=C2CC(O)=O)C(=O)C3=CC=C(Cl)C=C3,Indometacin,GST-Inhibitor
200,negative,C[C@H](C(O)=O)C1=CC(=CC=C1)C(=O)C2=CC=CC=C2,Ketoprofen,GST-Inhibitor
201,negative,NC1=NC(N)=C(N=N1)C2=C(Cl)C(Cl)=CC=C2,Lamotrigine,GST-Inducer
202,negative,OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O)[C@H](O)[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O[C@@H]5O[C@H](CO[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@@H](O)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]5O)[C@H]4O)[C@H]3O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Lentinan,GST-Inhibitor
203,negative,C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3,Levamisole,GST-Inducer
204,negative,CC[C@@H](N1CCCC1=O)C(N)=O,Levetiracetam,GST-Inducer
205,negative,N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,Melphalan,GST-Substrate
206,negative,COC1=CC=C(O)C=C1,Mequinol,GST-Inducer
207,negative,NCCS,Mercaptamine,GST-Inhibitor
208,negative,CN(CS([O-])(=O)=O)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2,Metamizole Sodium,GST-Inducer
209,negative,CSCC[C@H](N)C(O)=O,Methionine,GST-Inducer
210,negative,N=O,Nitric Oxide,GST-Inducer
211,negative,CCC[C@H](N[C@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC,Perindopril,GST-Inhibitor
212,negative,NC(=O)[C@]1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N3CCCCC3,Pipamperone,GST-Inducer
213,negative,Cl.CCCCCCNC(=N)NC(N)=N,Polihexanide,GST-Inhibitor
214,negative,CCCC1=CC(=O)NC(=S)N1,Propylthiouracil,GST-Inhibitor
215,negative,CCC1=C(C(N)=NC(N)=N1)C2=CC=C(Cl)C=C2,Pyrimethamine,GST-Inhibitor
216,negative,[O-]N=O,Sodium Nitrite,GST-Inhibitor
217,negative,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)C1=C/C3=CC=C(C=C3)S(C)=O,Sulindac,GST-Inducer
218,negative,CN1CC(=O)N2[C@H](CC3=C(NC4=CC=CC=C34)[C@H]2C5=CC=C6OCOC6=C5)C1=O,Tadalafil,GST-Inducer
219,negative,CN(C)[C@H]1[C@@H]2C[C@@H]3C(=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)C4=C(O)C=CC=C4[C@@]3(C)O,Tetracycline,GST-Inhibitor
220,negative,CC[Hg]SC1=C(C=CC=C1)C([O-])=O,Thiomersal,GST-Inhibitor
221,negative,S=P(N1CC1)(N2CC2)N3CC3,Thiotepa,GST-Substrate
222,negative,C[C@@H](C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2,Tiaprofenic Acid,GST-Inhibitor
223,negative,OC(=O)COC1=C(Cl)C(Cl)=C(C=C1)C(=O)C2=CC=CS2,Tienilic Acid,GST-Inhibitor
224,negative,OC(=O)CCCC[C@@H]1CCSS1,Tioctic Acid,GST-Inducer
225,negative,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,Adenosine,Sodiumbile_acid_cotransporter-Inducer
226,negative,COC1=CC=CC=C1OC2=C(NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)N=C(N=C2OCCO)C4=NC=CC=N4,Bosentan,Sodiumbile_acid_cotransporter-Inhibitor
227,negative,CCC1=CC=C(C=C1)[C@@H](C)CCC2=CC=C(C=C2)[N+](C)(C)C,Colestyramine,Sodiumbile_acid_cotransporter-Inducer
228,negative,CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1C=C[C@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O,Rosuvastatin,Sodiumbile_acid_cotransporter-Substrate
229,negative,NC1=CC=C(C=C1)C(O)=O,Aminobenzoic Acid,SUL-Substrate
230,negative,CN1CCC2=CC=CC3=C2[C@H]1CC4=C3C(O)=C(O)C=C4,Apomorphine,SUL-Substrate
231,negative,C1=CC=C(C=C1)C=CC(=O)O,Bemiparin,SUL-Substrate
232,negative,CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Budesonide,SUL-Substrate
233,negative,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2C(CCC[C@]12C)=CC=C3C[C@@H](O)C[C@H](O)C3=C,Calcitriol,SUL-Inducer
234,negative,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(N)(=O)=O)C(F)(F)F,Celecoxib,SUL-Inhibitor
235,negative,[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C,Cholic Acid,SUL-Substrate
236,negative,OC1=C(I)C=C(Cl)C2=C1N=CC=C2,Clioquinol,SUL-Inhibitor
237,negative,CSCC[C@H](NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C45)C(=O)NCC(O)=O,Corticotropin,SUL-Inducer
238,negative,C[C@]12CC[C@@H](O)C=C1CC[C@H]3[C@@H]4CC[C@](O)(C(=O)CO)[C@@]4(C)CC(=O)[C@H]23,Cortisone,SUL-Inhibitor
239,negative,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@@H](CC[C@]67O)C8=CC(=O)OC8)C4,Digitoxin,SUL-Substrate
240,negative,CN[C@@H](C)[C@H](O)C1=CC=CC=C1,Ephedrin,SUL-Substrate
241,negative,CNC[C@H](O)C1=CC(O)=C(O)C=C1,Epinephrine,SUL-Substrate
242,negative,OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O,Galactose,SUL-Substrate
243,negative,NC1=[N+]([O-])C(N)=NC(=C1)N2CCCCC2,Minoxidil,SUL-Substrate
244,negative,CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C,Promegestone,SUL-Inducer
245,negative,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,Pseudoephedrine,SUL-Substrate
246,negative,CC1=C(O)C(C=O)=C(COP(O)(O)=O)C=N1,Pyridoxal Phosphate,SUL-Inhibitor
247,negative,C[C@H](NCCC1=CC=C(O)C=C1)[C@H](O)C2=CC=C(O)C=C2,Ritodrine,SUL-Substrate
248,negative,OC(=O)CC(O)(CC(O)=O)C([O-])=O,Sodium Citrate,SUL-Inhibitor
249,negative,CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@H]2[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]5NC(=O)[C@@H](Cc6ccc(Oc7cc4cc(Oc8ccc2cc8Cl)c7O[C@@H]9O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]9NC(=O)C)c(Cl)c6)NC(=O)[C@H](N)c%10ccc(O)c(Oc%11cc(O)cc5c%11)c%10)c%12ccc(O)c(c%12)c%13c(O[C@H]%14O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]%14O)cc(O)cc%13[C@H](NC3=O)C(=O)O,Teicoplanin,SUL-Substrate
250,negative,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,Triamcinolone,SUL-Inducer
251,negative,OC1=C(OC2=C(Cl)C=C(Cl)C=C2)C=CC(Cl)=C1,Triclosan,SUL-Inhibitor
252,negative,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C3=CC=CC=C3)=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C4=CC=C(F)C=C4,Atorvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
253,negative,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O,Bezafibrate,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor
254,negative,COCC1=C(C2=CC=C(F)C=C2)C(C=C[C@@H](O)C[C@@H](O)CC(O)=O)=C(N=C1C(C)C)C(C)C,Cerivastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
255,negative,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)CC=CC)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)NC(=O)CN(C)C1=O)C(C)C,Ciclosporin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor
256,negative,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@@H](CC[C@]67O)C8=CC(=O)OC8)C4,Digoxin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
257,negative,CCOC(=O)[C@@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(O)=O,Enalapril,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
258,negative,O[C@@H](CC[C@H]1[C@H](N(C1=O)C2=CC=C(F)C=C2)C3=CC=C(O)C=C3)C4=CC=C(F)C=C4,Ezetimibe,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
259,negative,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,Gemfibrozil,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor
260,negative,C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN3CCN4CCN(CC(O)=O)CC(=O)O[In](OC(=O)C4)OC(=O)C3)C(=O)N[C@H](CN[C@H](C[C@H]5C=NC6=C5C=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)CC7=CC=CC=C7,Indium (111In) Pentetic Acid,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
261,negative,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C)C=CC=C3C)CC4=CC=CC=C4,Lopinavir,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor
262,negative,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,Lovastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
263,negative,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12,Pravastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
264,negative,CO[C@H]1C=CO[C@]2(C)OC3=C(C2=O)C4=C(O)C=C(NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C4C(O)=C3C,Rifamycin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor
265,negative,COC1=CC(=CC=C1O)[C@H]2OC3=C(O[C@@H]2CO)C=CC(=C3)[C@H]4OC5=CC(O)=CC(O)=C5C(=O)[C@@H]4O,Silymarin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor
266,negative,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,Simvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
267,negative,CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC(C)=CC=C2)C=CN=C1,Torasemide,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate
268,negative,CC(=O)OCC[N+](C)(C)C,Acetylcholin,Methyltransferase-Inducer
269,negative,CC(C)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CC4=CC=CC=C4)C(O)=O,Angiotensinamide,Methyltransferase-Inducer
270,negative,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C2=C3NC[C@@H](C)CC3=CC=C2,Argatroban,Methyltransferase-Inducer
271,negative,NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Azacitidine,Methyltransferase-Inhibitor
272,negative,CN1C=NC(=C1SC2=C3NC=NC3=NC=N2)[N+]([O-])=O,Azathioprine,Methyltransferase-Substrate
273,negative,NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F,Bendroflumethiazide,Methyltransferase-Inhibitor
274,negative,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,Captopril,Methyltransferase-Substrate
275,negative,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1,Chlorhexidine,Methyltransferase-Inhibitor
276,negative,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C2=CC=CC=N2,Chlorphenamine,Methyltransferase-Inducer
277,negative,NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1,Decitabine,Methyltransferase-Inhibitor
278,negative,CCN(CC)CCOC(=O)[C@@]1(CCCCC1)[C@H]2CCCCC2,Dicycloverine,Methyltransferase-Inhibitor
279,negative,COC1=CC=C(C=C1O)C2=CC(=O)C3=C(O2)C=C(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]5O)[C@H](O)[C@H](O)[C@H]4O)C=C3O,Diosmin,Methyltransferase-Inhibitor
280,negative,CN(CC(O)=O)C(=N)NP(O)(O)=O,Fosfocreatine,Methyltransferase-Inhibitor
281,negative,NN=C1NN=CC2=C1C=CC=C2,Hydralazine,Methyltransferase-Inducer
282,negative,CN1CCC(CC1)=C2C3=C(CC(=O)C4=C2C=CS4)C=CC=C3,Ketotifen,Methyltransferase-Inducer
283,negative,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O,Levodopa,Methyltransferase-Substrate
284,negative,CCN(CC)CCC[C@@H](C)NC1=C2C=C(OC)C=CC2=NC3=CC(Cl)=CC=C13,Mepacrine,Methyltransferase-Inhibitor
285,negative,NC1=CC(C(O)=O)=C(O)C=C1,Mesalazine,Methyltransferase-Inhibitor
286,negative,ClC1=CC=C(C=C1)C(=O)NCCN2CCOCC2,Moclobemide,Methyltransferase-Inhibitor
287,negative,OC(=O)C1=CC(=CC=C1O)N=NC2=CC(C(O)=O)=C(O)C=C2,Olsalazine,Methyltransferase-Inhibitor
288,negative,CNC(=O)OC1=CC2=C(C=C1)N(C)[C@H]3N(C)CC[C@@]23C,Physostigmine,Methyltransferase-Inhibitor
289,negative,CO[C@@H]([C@@H]1CC2=C(C(O)=C3C(O)=C(C)C(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)=CC3=C2)C(=O)[C@H]1O[C@H]6C[C@@H](O[C@H]7C[C@@H](O[C@H]8C[C@](C)(O)[C@H](O)[C@@H](C)O8)[C@H](O)[C@@H](C)O7)[C@H](O)[C@@H](C)O6)C(=O)[C@@H](O)[C@@H](C)O,Plicamycin,Methyltransferase-Inhibitor
290,negative,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1,Procaine,Methyltransferase-Inhibitor
291,negative,CC1=C(O)C(CO)=C(CO)C=N1,Pyridoxine (vit B6),Methyltransferase-Inhibitor
292,negative,[Se],Selenium Compounds,Methyltransferase-Inhibitor
293,negative,CN1N=NC2=C(N=CN2C1=O)C(N)=O,Temozolomide,Methyltransferase-Inhibitor
294,negative,CC1=CC=C(C=C1)C(=O)C2=CC(=C(O)C(O)=C2)[N+]([O-])=O,Tolcapone,Methyltransferase-Inhibitor
295,negative,COC1=C(O)C2=C3[C@@H](CC4=CC(OC5=CC6=C(CCN(C)[C@H]6CC7=CC=C(O2)C=C7)C=C5OC)=C(O)C=C4)[N+](C)(C)CCC3=C1,Tubocurarine,Methyltransferase-Inhibitor
296,negative,COC1=C(OC)C(=O)C(CC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)C)=C(C)C1=O,Ubidecarenone,Methyltransferase-Substrate
297,negative,[H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21,Varenicline,Methyltransferase-Inhibitor
298,negative,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(C)=O)[N@@+]5(C)CCCCC5)[C@@]2(C)C[C@@H]1N6CCCCC6,Vecuronium,Methyltransferase-Inhibitor
299,negative,C[C@@H]1OC(=O)[C@H](NC(=O)[C@H]2CC(=O)CCN2C(=O)[C@H](CC3=CC=C(C=C3)N(C)C)N(C)C(=O)[C@H]4CCCN4C(=O)[C@H](C)NC(=O)[C@@H]1NC(=O)C5=C(O)C=CC=N5)C6=CC=CC=C6,Virginiamycin,Methyltransferase-Inhibitor
300,negative,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,Vorinostat,Methyltransferase-Inhibitor
301,negative,CCN1N=NN(CCN2CC[C@](CC2)(COC)N(C(=O)CC)C3=CC=CC=C3)C1=O,Alfentanil,P450_HFLA-Substrate
302,negative,CC1=NN=C2CN=C(C3=CC=CC=C3)C4=C(C=CC(Cl)=C4)N12,Alprazolam,P450_HFLA-Substrate
303,negative,CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1C2=C(Cl)C=CC=C2)C(=O)OC,Amlodipine,P450_HFLA-Substrate
304,negative,ClC1=C(Cl)C(=CC=C1)N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2,Aripiprazole,P450_HFLA-Substrate
305,negative,COC1=CC=C(CCN2CC[C@@H](CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(F)C=C5)C=C1,Astemizole,P450_HFLA-Substrate
306,negative,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Atazanavir,P450_HFLA-Inhibitor
307,negative,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O,Aztreonam,P450_HFLA-Substrate
308,negative,O=C1C[C@]2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)C4=NC=CC=N4,Buspirone,P450_HFLA-Substrate
309,negative,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,Clarithromycin,P450_HFLA-Substrate
310,negative,CN1CCN(CC1)C2=NC3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3,Clotiapine,P450_HFLA-Substrate
311,negative,COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C,Codeine,P450_HFLA-Substrate
312,negative,CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1,Dextropropoxyphene,P450_HFLA-Inducer
313,negative,COC1=CC=C(C=C1)[C@@H]2SC3=CC=CC=C3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O,Diltiazem,P450_HFLA-Substrate
314,negative,CN(C)CCO[C@@](C)(C1=CC=CC=C1)C2=CC=CC=N2,Doxylamin,P450_HFLA-Inducer
315,negative,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]34O[C@@H]3C[C@@]5(C)[C@@H](CC[C@@]56CCC(=O)O6)[C@@H]14,Eplerenone,P450_HFLA-Substrate
316,negative,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O,Estriol,P450_HFLA-Substrate
317,negative,CCOC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C,Ethylmorphine,P450_HFLA-Substrate
318,negative,CCOC(=O)C1=C(C)NC(C)=C([C@@H]1C2=C(Cl)C(Cl)=CC=C2)C(=O)OC,Felodipine,P450_HFLA-Substrate
319,negative,CCC(=O)N([C@H]1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Fentanyl,P450_HFLA-Substrate
320,negative,[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O,Glycyrrhizic Acid,P450_HFLA-Inducer
321,negative,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@@H](O)C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@H](O)CC4=C3C=CC=C4)CC5=CC=CN=C5,Indinavir,P450_HFLA-Inhibitor
322,negative,CCC1=C2CN3C(=O)C4=C(C=C3C2=NC5=CC=C(OC(=O)N6CC[C@@H](CC6)N7CCCCC7)C=C15)[C@@](O)(CC)C(=O)OC4,Irinotecan,P450_HFLA-Substrate
323,negative,COC(=O)C1=C(C)NC(C)=C([C@H]1C2=CC=CC(=C2)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C3=CC=CC=C3)C4=CC=CC=C4,Lercanidipine,P450_HFLA-Substrate
324,negative,O=C1N(C2=CC=CC=C2)C3=C(C=CC=C3)C1(CC4=CC=NC=C4)CC5=CC=NC=C5,Linopirdine,P450_HFLA-Substrate
325,negative,COCC(=O)O[C@]3(CCN(C)CCCC1=NC2=C(N1)C=CC=C2)CCC4=C(C=CC(F)=C4)[C@@H]3C(C)C,Mibefradil,P450_HFLA-Inhibitor
326,negative,CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12,Midazolam,P450_HFLA-Inhibitor
327,negative,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C5=CC=C(C=C5)N(C)C,Mifepristone,P450_HFLA-Inhibitor
328,negative,CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(O)=O,Nateglinide,P450_HFLA-Substrate
329,negative,CCC1=NN(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)C(=O)N1CCOC4=CC=CC=C4,Nefazodone,P450_HFLA-Inhibitor
330,negative,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C,Nelfinavir,P450_HFLA-Inhibitor
331,negative,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C,Neostigmine,P450_HFLA-Inhibitor
332,negative,COC(=O)C1=C(C)NC(C)=C([C@@H]1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OCC(C)C,Nisoldipine,P450_HFLA-Substrate
333,negative,CCOC(=O)C1=C(C)NC(C)=C([C@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC,Nitrendipine,P450_HFLA-Substrate
334,negative,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Norethisterone,P450_HFLA-Substrate
335,negative,CCN1C=C(C(O)=O)C(=O)C2=C1C=C(N3CCNCC3)C(F)=C2,Norfloxacin,P450_HFLA-Inhibitor
336,negative,CC1=NC=C(N1C[C@H](O)CCl)[N+]([O-])=O,Ornidazole,P450_HFLA-Substrate
337,negative,O[C@@H]1N=C(C2=CC=CC=C2)C3=C(NC1=O)C=CC(Cl)=C3,Oxazepam,P450_HFLA-Substrate
338,negative,NNCCC1=CC=CC=C1,Phenelzine,P450_HFLA-Inhibitor
339,negative,CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1,Pleconaril,P450_HFLA-Inducer
340,negative,OCCOCCN1CCN(CC1)C2=NC3=C(SC4=C2C=CC=C4)C=CC=C3,Quetiapine,P450_HFLA-Substrate
341,negative,CO[C@H]1C=CO[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=CC=C[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H]1C)C(C=NN5CCN(CC5)[C@H]6CCCC6)=C(O)C4=C3C2=O,Rifapentine,P450_HFLA-Inducer
342,negative,CC1=C(CCN2CC[C@H](CC2)C3=NOC4=CC(F)=CC=C34)C(=O)N5CCCCC5=N1,Risperidone,P450_HFLA-Substrate
343,negative,OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCCCC2=CC=CC=C2,Salmeterol,P450_HFLA-Substrate
344,negative,CC(C)(C)NC(=O)[C@@H]1C[C@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(N)=O)NC(=O)C4=NC5=CC=CC=C5C=C4,Saquinavir,P450_HFLA-Substrate
345,negative,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@@H](C)[C@@H]2CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C(C)[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC,Sirolimus,P450_HFLA-Substrate
346,negative,CO[C@@H]1C[C@H](CC[C@H]1O)C=C(/C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@H]([C@H](C[C@@H](C)CC(C)=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)OC)[C@H](C[C@H]4C)OC,Tacrolimus,P450_HFLA-Substrate
347,negative,CC(C)(C)C1=CC=C(C=C1)[C@@H](O)CCCN2CC[C@@H](CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4,Terfenadine,P450_HFLA-Substrate
348,negative,ClC1=CC=CC(=C1)N2CCN(CCCN3N=C4C=CC=CN4C3=O)CC2,Trazodone,P450_HFLA-Substrate
349,negative,CC1=NN=C2CN=C(C3=C(Cl)C=CC=C3)C4=C(C=CC(Cl)=C4)N12,Triazolam,P450_HFLA-Substrate
350,negative,CC[C@]1(O)C[C@H]2CN(CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=CC6=C(C=C5OC)N(C=O)[C@H]7[C@](O)([C@H](OC(C)=O)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC)C1,Vincristine,P450_HFLA-Substrate
351,negative,NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2,Zalcitabine,P450_HFLA-Substrate
352,negative,CCN(C(C)=O)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N,Zaleplon,P450_HFLA-Substrate
353,negative,CCCC(=O)NC1=CC(C(C)=O)=C(OC[C@@H](O)CNC(C)C)C=C1,Acebutolol,2D6-Inhibitor
354,negative,CCC1C(O)N2C3CC1C4C(O)C5(CC24)C3N(C)C6=C5C=CC=C6,Ajmaline,2D6-Inhibitor
355,negative,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N3CCCC3)C=C2,Almotriptan,2D6-Substrate
356,negative,CC(C)NC[C@H](O)COC1=CC=CC=C1CC=C,Alprenolol,2D6-Substrate
357,negative,C[C@@H](N)CC1=CC=CC=C1,Amfetamine,2D6-Inhibitor
358,negative,NCCCC(O)=O,Aminobutyric Acid,2D6-Substrate
359,negative,CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1,Amodiaquine,2D6-Inhibitor
360,negative,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3,Amprenavir,2D6-Substrate
361,negative,COC1=C(NC2=C3C=CC=CC3=NC4=CC=CC=C24)C=CC(NS(C)(=O)=O)=C1,Amsacrine,2D6-Substrate
362,negative,CCN(CC)CCCN([C@H]1CC2=CC=CC=C2C1)C3=CC=CC=C3,Aprindine,2D6-Substrate
363,negative,CO[C@@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,Artemether,2D6-Substrate
364,negative,CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2,Atomoxetine,2D6-Inhibitor
365,negative,COC(=O)C1=C(C)NC(C)=C([C@@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)O[C@H]3CCN(C3)CC4=CC=CC=C4,Barnidipine,2D6-Inhibitor
366,negative,CC(C)NC[C@@H](O)COC1=CC=CC2=C1OC(=C2)C(C)=O,Befunolol,2D6-Substrate
367,negative,COC(=O)C1=C(C)NC(C)=C([C@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)O[C@@H]3CCCN(C3)CC4=CC=CC=C4,Benidipine,2D6-Inhibitor
368,negative,CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,Benzatropine,2D6-Substrate
369,negative,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1,Benzethonium,2D6-Substrate
370,negative,CC(C)COC[C@H](CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3,Bepridil,2D6-Substrate
371,negative,C[C@](O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F,Bicalutamide,2D6-Inhibitor
372,negative,O[C@](CCN1CCCCC1)([C@@H]2C[C@H]3C[C@@H]2C=C3)C4=CC=CC=C4,Biperiden,2D6-Inhibitor
373,negative,CC(C)NC[C@@H](O)COC1=CC=C(COCCOC(C)C)C=C1,Bisoprolol,2D6-Substrate
374,negative,CC(C)(C)N1CC[C@](CC1)(C2=CC=CC=C2)C3=CC=CC=C3,Budipine,2D6-Inhibitor
375,negative,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1,Buflomedil,2D6-Substrate
376,negative,CC1=CC(OC[C@@H](O)CNC(C)(C)C)=C(Cl)C=C1,Bupranolol,2D6-Substrate
377,negative,CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCC(=O)N2,Carteolol,2D6-Inhibitor
378,negative,CC1O[C@@]2(CS1)CN1CCC2CC1,Cevimeline,2D6-Substrate
379,negative,CNC1=NC2=C(C=C(Cl)C=C2)C(C3=CC=CC=C3)=[N+]([O-])C1,Chlordiazepoxide,2D6-Substrate
380,negative,C1CN=C(N1)[C@@H]2C[C@]2(C3=CC=CC=C3)C4=CC=CC=C4,Cibenzoline,2D6-Substrate
381,negative,CN1CCC[C@@H]1CCO[C@](C)(C2=CC=CC=C2)C3=CC=C(Cl)C=C3,Clemastine,2D6-Inhibitor
382,negative,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C(CCC[C@]12C)=CC=C3C[C@@H](O)CCC3=C,Colecalciferol,2D6-Inhibitor
383,negative,NC(=N)N1CCC2=C(C1)C=CC=C2,Debrisoquine,2D6-Substrate
384,negative,CC(C)NC1=CC=CN=C1N2CCN(CC2)C(=O)C3=CC4=CC(NS(C)(=O)=O)=CC=C4N3,Delavirdine,2D6-Inhibitor
385,negative,ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=C(CC2)C=CC=N4,Desloratadine,2D6-Inhibitor
386,negative,CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1,Desvenlafaxine,2D6-Substrate
387,negative,C[C@H](N)CC1=CC=CC=C1,Dexamfetamine,2D6-Inhibitor
388,negative,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1,Dexmedetomidine,2D6-Inhibitor
389,negative,COC1=CC=C2C[C@@H]3[C@@H]4CC[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C,Dihydrocodeine,2D6-Substrate
390,negative,CS(C)=O,Dimethyl Sulfoxide,2D6-Inhibitor
391,negative,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,Diphenhydramin,2D6-Substrate
392,negative,O=C1CN2[C@@H]3C[C@H](C[C@H]2C[C@H]1C3)OC(=O)C4=CNC5=CC=CC=C45,Dolasetron,2D6-Substrate
393,negative,COC1=C(OC)C=C2C(=O)[C@H](C[C@H]3CCN(CC3)CC4=CC=CC=C4)CC2=C1,Donepezil,2D6-Substrate
394,negative,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N3CCN(CC3)C(=O)[C@@H]4COC5=C(O4)C=CC=C5,Doxazosin,2D6-Substrate
395,negative,FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#C[C@H]3CC3,Efavirenz,2D6-Inhibitor
396,negative,CN1CCC[C@@H]1CC2=CNC3=C2C=C(CCS(=O)(=O)C4=CC=CC=C4)C=C3,Eletriptan,2D6-Substrate
397,negative,CC[C@H]1CN2CCC3=CC(OC)=C(OC)C=C3[C@@H]2C[C@@H]1C[C@H]4NCCC5=C4C=C(OC)C(OC)=C5,Emetine,2D6-Substrate
398,negative,COC1=CC=C(C=C1)C(=O)NC2=C(C=CC=C2)[C@H](C)CN3CCCCC3,Encainide,2D6-Substrate
399,negative,NC1=NC[C@H]2N1C3=C(CC4=C2C=CC=C4)C=CC=C3,Epinastine,2D6-Inhibitor
400,negative,CN(C)CCC[C@]1(OCC2=CC(=CC=C12)C#N)C3=CC=C(F)C=C3,Escitalopram,2D6-Substrate
401,negative,CCN[C@@H](C)CC1=CC=CC=C1,Etilamfetamine,2D6-Substrate
402,negative,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C,Fesoterodine,2D6-Substrate
403,negative,CC(C)(C(O)=O)C1=CC=C(C=C1)[C@@H](O)CCCN2CC[C@@H](CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4,Fexofenadine,2D6-Inhibitor
404,negative,COC1=CC=C(C[C@H](C)NC[C@@H](O)C2=CC=C(O)C(NC=O)=C2)C=C1,Formoterol,2D6-Substrate
405,negative,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24,Galantamine,2D6-Substrate
406,negative,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN4CCOCC4,Gefitinib,2D6-Inhibitor
407,negative,CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1,Gepirone,2D6-Substrate
408,negative,NC(=N)NC[C@H]1COC2=C(O1)C=CC=C2,Guanoxan,2D6-Substrate
409,negative,CCCCN(CCCC)CC[C@H](O)C1=C2C=CC(=CC2=C3C=C(Cl)C=C(Cl)C3=C1)C(F)(F)F,Halofantrine,2D6-Inhibitor
410,negative,Cl,Hydrochloric Acid,2D6-Inhibitor
411,negative,COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C,Hydrocodone,2D6-Substrate
412,negative,CN1CC[C@@]23[C@H]4CCC(=O)[C@@H]2OC5=C3C(C[C@@H]14)=CC=C5O,Hydromorphone,2D6-Substrate
413,negative,CCN(CCO)CCC[C@@H](C)NC1=CC=NC2=C1C=CC(Cl)=C2,Hydroxychloroquine,2D6-Inhibitor
414,negative,OCCOCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3,Hydroxyzine,2D6-Inhibitor
415,negative,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2C[C@@](O)(CC3=C2C(O)=C4C(=O)C5=CC=CC=C5C(=O)C4=C3O)C(C)=O,Idarubicin,2D6-Inhibitor
416,negative,O=C(N[C@H]1CCN(CC1)CCC2=CNC3=C2C=CC=C3)C4=CC=CC=C4,Indoramin,2D6-Substrate
417,negative,CCCCC1=N[C@@]2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5,Irbesartan,2D6-Inhibitor
418,negative,C[C@@H](CCC1=CC=CC=C1)NC[C@H](O)C2=CC=C(O)C(=C2)C(N)=O,Labetalol,2D6-Inhibitor
419,negative,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(C2=C1)=C34,Lisuride,2D6-Substrate
420,negative,CN(CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2)CC(=O)C4=CC=C(Cl)C=C4,Lofepramine,2D6-Substrate
421,negative,ClCCN(N=O)C(=O)N[C@H]1CCCCC1,Lomustine,2D6-Substrate
422,negative,CN(C)C(=O)C(CCN1CC[C@@](O)(CC1)C2=CC=C(Cl)C=C2)(C3=CC=CC=C3)C4=CC=CC=C4,Loperamide,2D6-Substrate
423,negative,CCOC(=O)N1CCC(CC1)=C2/C3=C(CCC4=C2N=CC=C4)C=C(Cl)C=C3,Loratadine,2D6-Inhibitor
424,negative,COC(=O)C1=C(C)NC(C)=C([C@@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5,Manidipine,2D6-Inhibitor
425,negative,C[C@H]1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1,Melperone,2D6-Inhibitor
426,negative,C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,Memantine,2D6-Inhibitor
427,negative,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1,Mepyramine,2D6-Inhibitor
428,negative,C1CN2CC[C@H]1[C@H](C2)CN3C4=C(SC5=C3C=CC=C5)C=CC=C4,Mequitazine,2D6-Substrate
429,negative,CN1CCCC[C@H]1CCN2C3=C(SC4=C2C=C(C=C4)S(C)=O)C=CC=C3,Mesoridazine,2D6-Substrate
430,negative,CN[C@@H](C)CC1=CC=CC=C1,Metamfetamine,2D6-Substrate
431,negative,CN[C@@H](C)CC1=C(OC)C=CC=C1,Methoxyphenamine,2D6-Substrate
432,negative,CCC1(CC)C(=O)NC[C@@H](C)C1=O,Methyprylon,2D6-Substrate
433,negative,COCCC1=CC=C(OC[C@H](O)CNC(C)C)C=C1,Metoprolol,2D6-Substrate
434,negative,COC1=CC([C@H](O)CNC(=O)CN)=C(OC)C=C1,Midodrine,2D6-Inhibitor
435,negative,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3,Minaprine,2D6-Substrate
436,negative,CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5O,Morphine,2D6-Substrate
437,negative,O[C@@H](CNC[C@@H](O)[C@@H]1CCC2=C(O1)C=CC(F)=C2)[C@H]3CCC4=CC(F)=CC=C4O3,Nebivolol,2D6-Substrate
438,negative,CC1=CC=NC2=C1NC(=O)C3=C(N=CC=C3)N2[C@H]4CC4,Nevirapine,2D6-Substrate
439,negative,CO[C@]12C[C@@H](COC(=O)C3=CC(Br)=CN=C3)CN(C)[C@@H]1CC4=CN(C)C5=CC=CC2=C45,Nicergoline,2D6-Substrate
440,negative,OC(=O)C1=CC=CN=C1,Nicotinic Acid,2D6-Inhibitor
441,negative,NC(=O)NN=CC1=CC=C(O1)[N+]([O-])=O,Nitrofural,2D6-Substrate
442,negative,NC[C@H](O)C1=CC=C(O)C=C1,Octopamine,2D6-Substrate
443,negative,OCCN1CCN(CCCN2C3=C(C=CC=C3)C=CC4=C2C=CC=C4)CC1,Opipramol,2D6-Substrate
444,negative,CN(C)CCO[C@H](C1=CC=CC=C1)C2=C(C)C=CC=C2,Orphenadrine (citrate),2D6-Inhibitor
445,negative,CC(C)NC[C@H]1CCC2=C(N1)C=C(C(CO)=C2)[N+]([O-])=O,Oxamniquine,2D6-Inhibitor
446,negative,C[C@@H](C(=O)NC1=CC(C)=CC=N1)C2=CC=CC(=C2)C(=O)C3=CC=CC=C3,Oxatomide,2D6-Inhibitor
447,negative,CC(C)NC[C@@H](O)COC1=C(OCC=C)C=CC=C1,Oxprenolol,2D6-Inhibitor
448,negative,CCN(CC)CC#CCOC(=O)[C@](O)([C@H]1CCCCC1)C2=CC=CC=C2,Oxybutynin,2D6-Inhibitor
449,negative,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(C)ON=C2C3=CC=CC=C3,Parecoxib,2D6-Inhibitor
450,negative,FC1=CC=C(C=C1)[C@@H]2CCNC[C@H]2COC3=CC4=C(OCO4)C=C3,Paroxetine,2D6-Inhibitor
451,negative,CCN(CC)CCOCCOC(=O)[C@]1(CCCC1)C2=CC=CC=C2,Pentoxyverine,2D6-Substrate
452,negative,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34,Pergolide,2D6-Inhibitor
453,negative,C1CC[C@H](CC1)C(C[C@H]2CCCCN2)[C@H]3CCCCC3,Perhexiline,2D6-Substrate
454,negative,NC(=N)NC(=N)NCCC1=CC=CC=C1,Phenformin,2D6-Substrate
455,negative,CC(C)(N)CC1=CC=CC=C1,Phentermine,2D6-Inhibitor
456,negative,CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CN2,Pindolol,2D6-Substrate
457,negative,CCC1=CC=C(CCOC2=CC=C(C[C@@H]3SC(=O)NC3=O)C=C2)N=C1,Pioglitazone,2D6-Inhibitor
458,negative,C1CNCCN1,Piperazine,2D6-Substrate
459,negative,CCC[N@+]12[C@H](O)[C@@H](CC)[C@@H]3C[C@H]1[C@@H]4N(C)C5=C(C=CC=C5)[C@]46C[C@H]2[C@H]3[C@H]6O,Prajmaline,2D6-Substrate
460,negative,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1,Procainamide,2D6-Substrate
461,negative,CN1CCN(CCCN2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1,Prochlorperazine,2D6-Substrate
462,negative,C[C@@H](CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C,Promethazine,2D6-Inhibitor
463,negative,CNCCC[C@H]1C2=C(C=CC=C2)C=CC3=C1C=CC=C3,Protriptyline,2D6-Substrate
464,negative,CN1CCCN=C1C=CC2=CC=CS2,Pyrantel,2D6-Substrate
465,negative,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,Reboxetine,2D6-Inducer
466,negative,CCN1CCC[C@H]1CNC(=O)C2=C(OC)C(Br)=CC=C2OC,Remoxipride,2D6-Substrate
467,negative,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,Rivastigmine,2D6-Inhibitor
468,negative,CN(CCOC1=CC=C(C[C@@H]2SC(=O)NC2=O)C=C1)C3=NC=CC=C3,Rosiglitazone,2D6-Inhibitor
469,negative,OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1,Roxatidine,2D6-Substrate
470,negative,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C5=CC(O)=C(O)C=C5)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,Rutoside,2D6-Inhibitor
471,negative,FC1=CC=C(C=C1)N2C=C([C@@H]3CCN(CC3)CCN4CCNC4=O)C5=CC(Cl)=CC=C25,Sertindole,2D6-Substrate
472,negative,C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](NC(=O)[C@@H](CO)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)[C@@H](CC6=CC=CC=C6)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCCCN)NC1=O)[C@H](C)O)[C@H](C)O)C(O)=O,Somatostatin,2D6-Inhibitor
473,negative,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1,Sparteine,2D6-Inhibitor
474,negative,NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=NN2C3=CC=CC=C3,Sulfaphenazole,2D6-Inhibitor
475,negative,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1,Tamsulosin,2D6-Substrate
476,negative,COC1=CC2=C(C=C1OC)[C@@H]3CC(=O)[C@@H](CC(C)C)CN3CC2,Tetrabenazine,2D6-Inhibitor
477,negative,COC1=CC=C2C[C@@H]3[C@H]4CC=C(OC(C)=O)[C@@H]5OC1=C2[C@]45CCN3C,Thebacon,2D6-Substrate
478,negative,CC(C)(C)NC[C@H](O)COC1=NSN=C1N2CCOCC2,Timolol,2D6-Substrate
479,negative,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)C(O)(C4=CC=CS4)C5=CC=CS5,Tiotropium Bromide,2D6-Substrate
480,negative,CC(C)N(CC[C@@H](C1=CC=CC=C1)C2=CC(C)=CC=C2O)C(C)C,Tolterodine,2D6-Substrate
481,negative,COC1=CC=CC(=C1)[C@@]2(O)CCCC[C@@H]2CN(C)C,Tramadol,2D6-Inhibitor
482,negative,O[C@@]1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC(=CC=C3)C(F)(F)F,Trifluperidol,2D6-Substrate
483,negative,C[C@H](CN(C)C)CN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,Trimipramine,2D6-Substrate
484,negative,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2,Tripelennamine,2D6-Inhibitor
485,negative,CC1=CC=C(C=C1)C(=C/CN2CCCC2)C3=CC=CC=N3,Triprolidine,2D6-Inhibitor
486,negative,CN1C2CCC1CC(C2)OC(=O)C3=CNC4=C3C=CC=C4,Tropisetron,2D6-Substrate
487,negative,COC1=CC=C(C=C1)[C@@H](CN(C)C)[C@@]2(O)CCCCC2,Venlafaxine,2D6-Inhibitor
488,negative,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1,Vernakalant,2D6-Substrate
489,negative,CC[C@]1(O)C[C@@H]2CN(CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=CC6=C(C=C5OC)N(C)[C@H]7[C@](O)([C@H](OC(C)=O)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC)C1,Vinblastine,2D6-Substrate
490,negative,CCC1=C[C@@H]2CN(C1)CC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@H]7[C@](O)([C@H](OC(C)=O)[C@]8(CC)C=CCN9CC[C@]7([C@H]89)C6=C5)C(=O)OC,Vinorelbine,2D6-Substrate
491,negative,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12,Yohimbin,2D6-Inhibitor
492,negative,OCCN1CCN(CCC=C2C3=CC=CC=C3SC4=C2C=C(Cl)C=C4)CC1,Zuclopenthixol,2D6-Substrate
493,negative,CC1=C(C=CC(=C1)N(C)C)CC(C)N,Amiflamine,2D6-Substrate
494,negative,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C,Aminopyrine,2D6-Substrate
495,negative,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,Amoxapine,2D6-Substrate
496,negative,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCCN3CCN(CC3)C4=NC=NC=C4OC,Avitriptan,2D6-Substrate
497,negative,COC1=CC(=C2C(=C1)C=C(O2)C3CCNCC3)Br,Brofaromine,2D6-Substrate
498,negative,CNC(=O)OC1=CC=CC2=CC=CC=C21,Carbaril,2D6-Substrate
499,negative,CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl,Chlorpyrifos,2D6-Substrate
500,negative,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)O,Dextrorphan,2D6-Substrate
501,negative,CCC(C)(C)NCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,Diprafenone,2D6-Substrate
502,negative,CCN1C(=O)N(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)N=C1CC,Etoperidone,2D6-Substrate
503,negative,CC(C)C1=CC(=C(C=C1)OC)CNC2C3CCN(C2C(C4=CC=CC=C4)C5=CC=CC=C5)CC3,Ezlopitant,2D6-Substrate
504,negative,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,Iloperidone,2D6-Substrate
505,negative,CN[C@]1(CCCCC1=O)C2=C(Cl)C=CC=C2,Ketamine,2D6-Substrate
506,negative,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Lidocaine,2D6-Substrate
507,negative,C1CN(CCN1)C2=CC(=CC=C2)Cl,m-Chlorophenylpiperazine,2D6-Substrate
508,negative,CC1=CC(=CC(=C1SC)C)OC(=O)NC,Methiocarb,2D6-Substrate
509,negative,CN1CCC=C(C1)C=NOC,Milameline,2D6-Substrate
510,negative,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C,Molindone,2D6-Substrate
511,negative,COC1=C2C3=C(CC4C5C3(CCN4)C(O2)C(C=C5)O)C=C1,Norcodeine,2D6-Substrate
512,negative,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,Orphenadrine,2D6-Substrate
513,negative,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,Papaverine,2D6-Substrate
514,negative,CCOP(=S)(OCC)OC1=CC=C(C=C1)[N+](=O)[O-],Parathion,2D6-Substrate
515,negative,CC(C)(C)NCC(COC1=CC=CC=C1C2CCCC2)O,Penbutolol,2D6-Substrate
516,negative,CC1C2CC3=C(C1(CCN2CC=C(C)C)C)C=C(C=C3)O,Pentazocine,2D6-Substrate
517,negative,CCOC(=O)[C@@]1(CCN(C)CC1)C2=CC=CC=C2,Pethidine,2D6-Substrate
518,negative,C[C@@H](NC(NC#N)=NC1=CC=NC=C1)C(C)(C)C,Pinacidil,2D6-Substrate
519,negative,CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,Pregnenolone,2D6-Substrate
520,negative,CN(C)S(=O)(=O)CCNC(=O)N(CCCl)N=O,Tauromustine,2D6-Substrate
521,negative,CCN(CC)C(=O)NC1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)C,Terguride,2D6-Substrate
522,negative,CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(O)=O)C3=C(C)C=CS3,Tiagabine,2D6-Substrate
523,negative,C(Cl)(Cl)Cl,Trichloromethane,2D6-Substrate
524,negative,CC1=C(C2=CC=C(C=C2)S(N)(=O)=O)C(=NO1)C3=CC=CC=C3,Valdecoxib,2D6-Substrate
525,negative,COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O,Yohimbine,2D6-Substrate
526,negative,NC1=NC2=C(N=CN2[C@H]3C[C@@H](CO)C=C3)C(N[C@H]4CC4)=N1,Abacavir,-
527,negative,CC(C)OC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC(=C3)OCC4=CC=CC=C4,Abecarnil,-
528,negative,OC(=O)COC(=O)CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl,Aceclofenac,-
529,negative,CC(=O)C[C@H](C1=CC=C(C=C1)[N+]([O-])=O)C2=C(O)C3=C(OC2=O)C=CC=C3,Acenocoumarol,-
530,negative,CC(=O)NC1=CC=CC=C1,Acetanilide,-
531,negative,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,Acetazolamide,-
532,negative,CC(=O)C,Acetone,-
533,negative,CC(=O)OC1=CC=CC=C1C(=O)O,Acetylsalicylic acid,-
534,negative,CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C4=C(C=CC(Cl)=C4)N12,Adinazolam,-
535,negative,CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl,Alpidem,-
536,negative,NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br,Ambroxol,-
537,negative,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,Aminoglutethimide,-
538,negative,C1=CC=C(C=C1)N,Aniline,-
539,negative,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2=O,Anthraquinone,-
540,negative,C[C@H]1CC[C@H]2[C@H](C)[C@H](O[C@H]3O[C@]4(C)CC[C@H]1[C@]23OO4)OC(=O)CCC(O)=O,Artesunate,-
541,negative,OC1=C([C@H]2CC[C@@H](CC2)C3=CC=C(Cl)C=C3)C(=O)C4=C(C=CC=C4)C1=O,Atovaquone,-
542,negative,CC(C)C1=C(C(=CC=C1)C(C)C)OS(=O)(=O)NC(=O)CC2=C(C=C(C=C2C(C)C)C(C)C)C(C)C,Avasimibe,-
543,negative,C1CNCCC1C(C2=CC=CC=C2)(C3=CC=CC=C3)O,Azacyclonol,-
544,negative,CCC1(CC(C2(C(CCC3(C2C(=O)CC3)C(C1O)C)C)C)OC(=O)CSC4=NNC(=N4)N)C,Azamulin,-
545,negative,CCC[C@H]1C(=O)N2N(C1=O)C(=NC3=C2C=C(C)C=C3)N(C)C,Azapropazone,-
546,negative,CN1CCC(CC1)=C2/C3=C(CCC4=C2N=CC=C4)C=CC=C3,Azatadine,-
547,negative,CN1CCN(CC1)CCCCN2C(=O)CN(C2=O)N=CC3=CC=C(O3)C4=CC=C(C=C4)Cl,Azimilide,-
548,negative,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Azithromycin,-
549,negative,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C3=CC=CC=C3O1,Benzbromarone,-
550,negative,C1=CC=CC=C1,Benzene,-
551,negative,CC(CC1=CC=CC=C1)N(C)CC2=CC=CC=C2,Benzfetamine,-
552,negative,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,Betamethasone,-
553,negative,CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(O)=O)C(C)(C)CCC2(C)C,Bexarotene,-
554,negative,CCC(C1=CC(=C(C=C1)O)F)C(C)C2=CC(=C(C=C2)O)F,Bifluranol,-
555,negative,CC12CCC3C(C1CCC2O)CCC4=CC(=O)C=CC34C,Boldenone,-
556,negative,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,Brinzolamide,-
557,negative,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=CC=CC(C4=C3)=C56)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C,Bromocriptine,-
558,negative,C1=CC=C(C=C1)C2=C(C(=O)NC(=N2)N)Br,Bropirimine,-
559,negative,CC1=NN=C2CN=C(C3=C(Cl)C=CC=C3)C4=C(SC(Br)=C4)N12,Brotizolam,-
560,negative,C1C(N(C2=C(N1)N=C(N=C2[O-])N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)[O-])C(=O)O.[Ca+2],Calcium folinate,-
561,negative,CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=NN5,Candesartan,-
562,negative,CC(C)C1=C(N(C(=N1)COC(=O)N)CC2=CC=NC=C2)SC3=CC(=CC(=C3)Cl)Cl,Capravirine,-
563,negative,CCOC(=O)N1C=CN(C1=S)C,Carbimazole,-
564,negative,CCC[C@@](C)(COC(N)=O)COC(=O)NC(C)C,Carisoprodol,-
565,negative,CC(C(=O)C1=CC=CC=C1)N,Cathinone,-
566,negative,CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C,Chenodeoxycholic acid,-
567,negative,C(C(Cl)(Cl)Cl)(O)O,Chloral hydrate,-
568,negative,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,Chloramphenicol,-
569,negative,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Chlormadinone,-
570,negative,COCCOC(=O)C1=C(C)NC(C)=C([C@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCC=CC3=CC=CC=C3,Cilnidipine,-
571,negative,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,Clindamycin,-
572,negative,CC(C)N=C1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5,Clofazimine,-
573,negative,CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl,Clofibric acid,-
574,negative,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,Cortisol,-
575,negative,CN1C(CCC1=O)C2=CN=CC=C2,Cotinine,-
576,negative,C1=CC=C2C(=C1)C=CC(=O)O2,Coumarin,-
577,negative,CCN(CC)CCS(=O)(=O)C1CCN2C1C(=O)OC(C(C=CC(=O)NCC=CC(=CC(CC(=O)CC3=NC(=CO3)C2=O)O)C)C)C(C)C,Dalfopristin,-
578,negative,[O-][N+](=O)C1=CC=C(C=C1)C2=CC=C(O2)C=NN3CC(=O)NC3=O,Dantrolene,-
579,negative,C1=CC(=CC=C1C(=O)O)OCCN2C=CN=C2,Dazoxiben,-
580,negative,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Desogestrel,-
581,negative,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl,Dexloxiglumide,-
582,negative,C1C2C3C(C1C4C2O4)C5(C(=C(C3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Dieldrin,-
583,negative,CN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F,Difloxacin,-
584,negative,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,Dihydroergotamine,-
585,negative,CS(=O)C,Dimethyl sulfoxide,-
586,negative,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O.[OH-].[K+].[K+],Dipotassium clorazepate,-
587,negative,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]4N[C@@H](COCCOC)O[C@H]([C@H]4C)[C@]1(C)O,Dirithromycin,-
588,negative,CC(C)N(CC[C@](C(N)=O)(C1=CC=CC=C1)C2=CC=CC=N2)C(C)C,Disopyramide,-
589,negative,CC1=CC(=C(C=C1S(=O)(=O)N)S(=O)(=O)N)Cl,Disulfamide,-
590,negative,CCN(CC)C(=S)[S-].[Na+],Ditiocarb sodium,-
591,negative,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC2=CC=C(NS(C)(=O)=O)C=C2,Dofetilide,-
592,negative,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C4=C(O)C=CC=C14,Doxycycline,-
593,negative,CCCCCC1=CC2=C([C@@H]3C=C(C)CC[C@H]3C(C)(C)O2)C(O)=C1,Dronabinol,-
594,negative,CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,Drospirenone,-
595,negative,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC5=CC(=CC=C5C(F)(F)F)C(F)(F)F,Dutasteride,-
596,negative,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CC[C@H](CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,Ebastine,-
597,negative,C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br,Ebrotidine,-
598,negative,CNC(=O)C1=CC(=CC=C1)NCC(=O)NCCC2=CC(=C(C=C2)OC)OC,Ecabapide,-
599,negative,CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5,Efonidipine,-
600,negative,CCCCC1=NC=C(C=C(/CC2=CC=CS2)C(O)=O)N1CC3=CC=C(C=C3)C(O)=O,Eprosartan,-
601,negative,CCC1=CC=CC=C1,Ethylbenzene,-
602,negative,CC[C@@]12CC(=C)[C@H]3[C@H](CCC4=CC(=O)CC[C@@H]34)[C@@H]1CC[C@@]2(O)C#C,Etonogestrel,-
603,negative,CO[C@@H]1C[C@@H](CC[C@H]1OCCO)C[C@@H](C)[C@@H]2CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C(C)[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC,Everolimus,-
604,negative,C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N,Fadrozole,-
605,negative,NC(N)=NC1=NC(CSCCC(N)=N/S(N)(=O)=O)=CS1,Famotidine,-
606,negative,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2,Fenofibrate,-
607,negative,COSC1=CN(C)C2=C(C=CC(F)=C2)C1=O,Flosequinan,-
608,negative,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=C(Cl)C=CC=C4F,Flucloxacillin,-
609,negative,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,Flufenamic acid,-
610,negative,C1C2C(CN1)OC3=C(O2)C=CC=C3F,Fluparoxan,-
611,negative,C[C@H](C(O)=O)C1=CC=C(C(F)=C1)C2=CC=CC=C2,Flurbiprofen,-
612,negative,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Flurithromycin,-
613,negative,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF,Fluticasone,-
614,negative,OP(O)(=O)OCN1C(=O)N[C@](C1=O)(C2=CC=CC=C2)C3=CC=CC=C3,Fosphenytoin,-
615,negative,CC1=NC2=C(N1)C(=O)N(C(=O)N2CC3=CC=CO3)C,Furafylline,-
616,negative,COC1=C(OC)C=C(CCN(C)CCC[C@@](C#N)(C(C)C)C2=CC(OC)=C(OC)C(OC)=C2)C=C1,Gallopamil,-
617,negative,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)(C)O)C)C,Ganaxolone,-
618,negative,CCC12CCC3C(C1C=CC2(C#C)O)CCC4=CC(=O)CCC34,Gestodene,-
619,negative,COC1=C(C=C(Cl)C=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]3CCCCC3,Glibenclamide,-
620,negative,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2,Gliclazide,-
621,negative,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@@H]3CC[C@@H](C)CC3)C1=O,Glimepiride,-
622,negative,C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-],Glyceryl trinitrate,-
623,negative,C[C@H]1CN(CCN1)C2=C(F)C(C)=C3C(=O)C(=CN([C@@H]4CC4)C3=C2)C(O)=O,Grepafloxacin,-
624,negative,C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl,Guanabenz,-
625,negative,CN1CCCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,Homochlorcyclizine,-
626,negative,CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,Ibutilide,-
627,negative,C1=CC=C(C=C1)C(=CCCCCC(=O)O)C2=CN=CC=C2,Isbogrel,-
628,negative,C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O[N+](=O)[O-],Isosorbide dinitrate,-
629,negative,COC(=O)C1=C(C)NC(C)=C([C@H]1C2=CC=CC3=NON=C23)C(=O)OC(C)C,Isradipine,-
630,negative,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]3C[C@@H](CC=C(C)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)C=CC=C6/CO[C@@H]7[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]67O)O2,Ivermectin,-
631,negative,CO[C@H]1[C@@H](CC(=O)O[C@H](C)CC=CC=C[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)OC(C)=O,Josamycin,-
632,negative,CCOC(=O)C1=C(C)NC(C)=C([C@@H]1C2=C(C=CC=C2)C=CC(=O)OC(C)(C)C)C(=O)OCC,Lacidipine,-
633,negative,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,Leflunomide,-
634,negative,C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4,Levofloxacin,-
635,negative,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)[O-])N.[Na+],Levothyroxine sodium,-
636,negative,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4,Liarozole,-
637,negative,CC12CC(C3=C4CCC(=O)C=C4CCC3C1CCC2(C=CCO)O)C5=CC=C(C=C5)N(C)C,Lilopristone,-
638,negative,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,Linezolid,-
639,negative,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,Liothyronine,-
640,negative,CC(CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O,Lisofylline,-
641,negative,C1CNCCC1OCC2=CC3=CC=CC=C3C=C2,Litoxetine,-
642,negative,COC1=CC(=O)OC1C(C2=CC=CC=C2Cl)O,Losigamone,-
643,negative,CCCCN(CCCC)CC(C1=CC(=CC2=C1C3=C(C2=CC4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O,Lumefantrine,-
644,negative,COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C3=CC=CC=C3,Mebendazole,-
645,negative,CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2,Medifoxamine,-
646,negative,C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(O)C(C)=O)[C@@]4(C)CCC(=O)C=C14,Medroxyprogesterone,-
647,negative,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,Mefenamic acid,-
648,negative,CC1=C(C=CC=C1)N2C(C)=NC3=C(C=CC=C3)C2=O,Methaqualone,-
649,negative,CC(=NOC(=O)NC)SC,Methomyl,-
650,negative,COC1=C2OC(=O)C=CC2=CC3=C1OC=C3,Methoxsalen,-
651,negative,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(C2=C1)=C34,Methylergometrine,-
652,negative,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2,Methylphenidate,-
653,negative,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)C=CC(=O)C=C14,Methylprednisolone,-
654,negative,CC1=NC=C(N1CCO)[N+]([O-])=O,Metronidazole,-
655,negative,CCC(C)C(=O)OC1CCC=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O,Mevastatin,-
656,negative,CC1COC2(N1CC(=O)NC3=C2C=C(C=C3)Cl)C4=CC=CC=C4Cl,Mexazolam,-
657,negative,CCC(=O)O[C@@H]1CC(=O)O[C@@H](C)CC=CC=C[C@@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@H](OC(=O)CC)[C@@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H]1OC,Midecamycin,-
658,negative,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,Milnacipran,-
659,negative,CC(C)(O)C1=C(CC[C@@H](SC[C@]2(CC2)CC(O)=O)C3=CC(=CC=C3)C=CC4=NC5=CC(Cl)=CC=C5C=C4)C=CC=C1,Montelukast,-
660,negative,CCOC(=O)NC1=CC2=C(SC3=C(C=CC=C3)N2C(=O)CCN4CCOCC4)C=C1,Moracizine,-
661,negative,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,Mosapride,-
662,negative,CCOC1=C(C2=CC=CC=C2C=C1)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,Nafcillin,-
663,negative,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,Nalidixic acid,-
664,negative,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O,Nefiracetam,-
665,negative,OC1=C(C=C(Cl)C=C1)C(=O)NC2=C(Cl)C=C(C=C2)[N+]([O-])=O,Niclosamide,-
666,negative,CCCOCCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOCCC)C)C,Niludipine,-
667,negative,COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC(C)C,Nimodipine,-
668,negative,C1COCCN1CCN2C=NC=C2[N+](=O)[O-],Nimorazole,-
669,negative,NN=O,Nitrosamine,-
670,negative,CN(C)CCC=C1C2=C(COC3=C1C=C(CC(O)=O)C=C3)C=CC=C2,Olopatadine,-
671,negative,CC1=C(SSC1=S)C2=NC=CN=C2,Oltipraz,-
672,negative,C1CC(N2C(C1)SCCC(C2=O)NC(=O)C(CC3=CC=CC=C3)S)C(=O)O,Omapatrilat,-
673,negative,NC(=O)N1C2=C(CC(=O)C3=C1C=CC=C3)C=CC=C2,Oxcarbazepine,-
674,negative,ClC1=CC(Cl)=C(CON=C(/CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C=C1,Oxiconazole,-
675,negative,CCOC(=O)C1=C(NC(=C(C1C2=C3C(=CC=C2)OCO3)C(=O)OC)C)C,Oxodipine,-
676,negative,CCN1C=C(C(O)=O)C(=O)C2=C1C=C(N3CCN(C)CC3)C(F)=C2,Pefloxacin,-
677,negative,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,Pentamidine,-
678,negative,C1CCC(CC1)(C2=CC=CC=C2)N3CCCCC3,Phencyclidine,-
679,negative,CC[C@H](C1=CC=CC=C1)C2=C(O)C3=C(OC2=O)C=CC=C3,Phenprocoumon,-
680,negative,CN1C(=O)C[C@@H](C1=O)C2=CC=CC=C2,Phensuximide,-
681,negative,CCCC[C@H]1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,Phenylbutazone,-
682,negative,CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCNCC3)C(=O)O,Pipemidic acid,-
683,negative,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=C(C=CC=C3)S1(=O)=O,Piroxicam,-
684,negative,CC12CCC3C(C1CCC2=O)CCC4=CC(=O)CCC34CC#C,Plomestane,-
685,negative,CCCN[C@@H]1CCC2=C(C1)SC(N)=N2,Pramipexole,-
686,negative,CC1=C(C(C(=C(N1)C)C(=O)OCC=CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,Pranidipine,-
687,negative,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisolone,-
688,negative,CC[C@@]1(C(=O)NCNC1=O)C2=CC=CC=C2,Primidone,-
689,negative,CCCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(CC)CC,Proadifen,-
690,negative,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O,Probenecid,-
691,negative,CCCO,Propanol,-
692,negative,C[N+]1=CC=CC(=C1)OC(=O)N(C)C.[Br-],Pyridostigmine bromide,-
693,negative,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,Quercetin,-
694,negative,CCCN1CCCC2C1CC3=CN=C(N=C3C2)N,Quinelorane,-
695,negative,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Quinine,-
696,negative,CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CC(C(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CSC6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C,Quinupristin,-
697,negative,COCCCOC1=C(C)C(CC(=O)C2=NC3=C(N2)C=CC=C3)=NC=C1,Rabeprazole,-
698,negative,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,Ranolazine,-
699,negative,C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl,Rebamipide,-
700,negative,CC(CC1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)CN,Remacemide,-
701,negative,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N3CCCCC3)=C1)C(O)=O,Repaglinide,-
702,negative,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C6=CC(OC)=C(OC)C(OC)=C6,Reserpine,-
703,negative,CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N,Resiquimod,-
704,negative,CCCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(=O)CC)O[C@@H]2[C@@H](C)O[C@@H](O[C@H]3[C@@H](CC=O)C[C@@H](C)[C@@H](O)C=CC=CC[C@@H](C)OC(=O)C[C@@H](O)[C@@H]3OC)[C@H](O)[C@H]2N(C)C,Rokitamycin,-
705,negative,CN(C1=CC=CC=C1)C(=O)C2=C(O)C3=C(C=CC=C3)N(C)C2=O,Roquinimex,-
706,negative,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@](C)(OC)[C@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]3O[C@@H](C)C[C@@H]([C@@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,Roxithromycin,-
707,negative,CC1=CC(CN2CCC(CC2)=C3/C4=C(CCC5=C3N=CC=C5)C=C(Cl)C=C4)=CN=C1,Rupatadine,-
708,negative,CC(C)(C)NC[C@@H](O)C1=CC=C(O)C(CO)=C1,Salbutamol,-
709,negative,C1=CC=C(C(=C1)C(=O)O)O,Salicylic acid,-
710,negative,CCC[C@@H](C)[C@]1(CC=C)C(=O)NC(=O)NC1=O,Secobarbital,-
711,negative,CC1=C(C)C(=O)C([C@H](CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O,Seratrodast,-
712,negative,CC(C)C[C@@H](N(C)C)[C@]1(CCC1)C2=CC=C(Cl)C=C2,Sibutramine,-
713,negative,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13,Spironolactone,-
714,negative,CCC(=O)N(C1=CC=CC=C1)[C@]2(CCN(CCC3=CC=CS3)CC2)COC,Sufentanil,-
715,negative,COC1=NC(OC)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1,Sulfadimethoxine,-
716,negative,CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1,Sulfadimidine,-
717,negative,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C,Sulfafurazole,-
718,negative,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,Sulfamethoxazole,-
719,negative,CC1=C(C)N=C(NS(=O)(=O)C2=CC=C(N)C=C2)O1,Sulfamoxole,-
720,negative,NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=N2,Sulfapyridine,-
721,negative,OC(=O)C1=C(O)C=CC(=C1)N=NC2=CC=C(C=C2)S(=O)(=O)NC3=CC=CC=N3,Sulfasalazine,-
722,negative,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,Sulfinpyrazone,-
723,negative,CCN1CCC[C@H]1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O,Sulpiride,-
724,negative,CC1=NC2=C(CCC(=O)N2CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(C)=N1,Tasosartan,-
725,negative,CCCCOC(=O)C(=O)NC1=CC=CC(=C1)C2=NNN=N2,Tazanolast,-
726,negative,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)CC2C(=O)NCS2,Tazofelone,-
727,negative,C1CNCCC1NC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Tecastemizole,-
728,negative,CCCC1=NC2=C(C)C=C(C=C2N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C(O)=O)C5=NC6=CC=CC=C6N5C,Telmisartan,-
729,negative,CN1C(=O)[C@H](O)N=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3,Temazepam,-
730,negative,COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)C6=CC=CS6)C7=C2C=C8OCOC8=C7,Teniposide,-
731,negative,CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,Tenofovir,-
732,negative,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=C(C=CS3)S1(=O)=O,Tenoxicam,-
733,negative,CC12CCC3C(C1CCC(=O)O2)CCC4=CC(=O)C=CC34C,Testolactone,-
734,negative,CC(C)C1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC,Tezosentan,-
735,negative,C1CN(CCN1CCO)C(=O)CN2C3=C(C=CC(=C3)Cl)SC2=O,Tiaramide,-
736,negative,C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,Tienilic acid,-
737,negative,C1=CC=C2C(=C1)NC(=N2)S(=O)CC3=CC=CC=N3,Timoprazole,-
738,negative,CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4,Tipranavir,-
739,negative,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN5CCN(CC5)C6=CC(=NC(=N6)N7CCCC7)N8CCCC8,Tirilazad,-
740,negative,C[C@H](N)C(=O)NC1=C(C)C=CC=C1C,Tocainide,-
741,negative,CC1=CC=CC=C1,Toluene,-
742,negative,CC1(C)O[C@H]2CO[C@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@H]2O1,Topiramate,-
743,negative,CCN(CC)C1=CC(=NC2=NC=NN12)C,Trapidil,-
744,negative,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,Trimetazidine,-
745,negative,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,Trimetrexate,-
746,negative,ClCCN(CCCl)[P@]1(=O)OCCCN1CCCl,Trofosfamide,-
747,negative,C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],Trospium chloride,-
748,negative,CCCC(CCC)C(=O)O,Valproic acid,-
749,negative,CC=CCC(C)C(=O)C1C(=O)NC(C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C,Valspodar,-
750,negative,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Vanoxerine,-
751,negative,COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC,Vesnarinone,-
752,negative,CC[C@]1(O)C[C@H]2CN(CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=CC6=C(C=C5OC)N(C)[C@H]7[C@](O)([C@H](O)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(N)=O)C1,Vindesine,-
753,negative,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN2C=NC=N2)C3=C(F)C=C(F)C=C3,Voriconazole,-
754,negative,CC(C1=CC2=C(C=C1)SC3=CC=CC=C3C(=O)C2)C(=O)O,Zaltoprofen,-
755,negative,CC1(CC2=C(O1)C(=CC(=C2)Cl)C(=O)NC3CC4CCC(C3)N4C)C,Zatosetron,-
756,negative,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,Zidovudine,-
757,negative,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,Zileuton,-
758,negative,NS(=O)(=O)CC1=NOC2=C1C=CC=C2,Zonisamide,-
759,negative,C1=CC2=C(C=C1Cl)N=C(O2)N,Zoxazolamine,-
760,negative,O[C@]1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3,Bromperidol,2D6-Substrate
761,negative,CCC1=CC=CC2=C1OC(=C2)C(CNC(C)(C)C)O,Bufuralol,2D6-Substrate
762,negative,CC(C)(C)NCC(COC1=CC=CC=C1C#N)O,Bunitrolol,2D6-Substrate
763,negative,C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4,Cinnarizine,2D6-Substrate
764,negative,CNCCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Demethylcitalopram,2D6-Substrate
765,negative,CN1CCN(CC1)C2=NC3=C(CC4=CC=CC=C42)C=CC(=C3)F,Fluperlapine,2D6-Substrate
766,negative,CC(CC1=CC=C(C=C1)O)N,Hydroxyamfetamine,2D6-Substrate
767,negative,C1=CC=C(C=C1)C(CCN)OC2=CC=C(C=C2)C(F)(F)F,Norfluoxetine,2D6-Substrate
768,negative,C1CCC2C(C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54,Perospirone,2D6-Substrate
769,negative,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,Abiraterone,-
770,negative,CNN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O,Amifloxacin,-
771,negative,CC1=C(C(C(=C(N1)C)C(=O)OCC(=O)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,Aranidipine,-
772,negative,CC1=CC(=O)C=C2C1(C3CCC4(C(C3CC2)CCC4=O)C)C,Atamestane,-
773,negative,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Beclometasone,-
774,negative,OC(=O)COCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3,Cetirizine,-
775,negative,CC(C)N=C(N)N=C(N)NC1=CC(=C(C=C1)Cl)Cl,Chlorproguanil,-
776,negative,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C3=C(Cl)C=CC=C3)C=C1,Clonazepam,-
777,negative,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4C(=O)CO)C)O,Corticosterone,-
778,negative,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2,Delapril,-
779,negative,CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C,Emedastine,-
780,negative,CCOCN1C(=C(C(=O)NC1=O)C(C)C)CC2=CC=CC=C2,Emivirine,-
781,negative,CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2,Enoxacin,-
782,negative,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(C2=C1)=C34,Ergometrine,-
783,negative,CCN1C(=O)N[C@H](C1=O)C2=CC=CC=C2,Ethotoin,-
784,negative,COC1=C(N2CCN[C@@H](C)C2)C(F)=CC3=C1N(C=C(C(O)=O)C3=O)[C@H]4CC4,Gatifloxacin,-
785,negative,CC1=CC=C(N=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]3CCCCC3,Glipizide,-
786,negative,CCC1CN2CCC1CC2C(C3=C4C=C(C=CC4=NC=C3)OC)O,Hydroquinidine,-
787,negative,CN1C(CCCC1CC(=O)C2=CC=CC=C2)CC(C3=CC=CC=C3)O,Lobeline,-
788,negative,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O,Lornoxicam,-
789,negative,CCCCC1=NC(Cl)=C(CO)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4,Losartan,-
790,negative,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C3=CC=CC=C3S1(=O)=O,Meloxicam,-
791,negative,CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)OC,Mestranol,-
792,negative,CC[C@]1(C(=O)NC(=O)N(C)C1=O)C2=CC=CC=C2,Methylphenobarbital,-
793,negative,NC(=O)CS(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,Modafinil,-
794,negative,CC1(C)NC(=O)N(C2=CC(=C(C=C2)[N+]([O-])=O)C(F)(F)F)C1=O,Nilutamide,-
795,negative,ClC1=CC2=C(NC(=O)CN=C2C3=CC=CC=C3)C=C1,Nordazepam,-
796,negative,CC12CC(C3=C4CCC(=O)C=C4CCC3C1CCC2(CCCO)O)C5=CC=C(C=C5)N(C)C,Onapristone,-
797,negative,C[C@H](CN(C)C)CN1C2=C(C=CC=C2)S(=O)(=O)C3=C1C=CC=C3,Oxomemazine,-
798,negative,CN1C=NC2=C1C(=O)N(C(=O)N2)C,Paraxanthine,-
799,negative,CCC[C@@H](C)[C@@]1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-
800,negative,CC1=C(C(=CC=C1)C)NC(=O)CC23CCCN2CCC3,Pilsicainide,-
801,negative,CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)OC,Pimobendan,-
802,negative,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisone,-
803,negative,CCC1(CCC(=O)NC1=O)C2=CC=NC=C2,Rogletimide,-
804,negative,CC(C)(C)C(C=CC1=CC2=C(C=C1)OCO2)O,Stiripentol,-
805,negative,C=CC1=CC=CC=C1,Styrene,-
806,negative,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N,Sulfadoxine,-
807,negative,CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Sulfamerazine,-
808,negative,CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1,Sulfamethizole,-
809,negative,CC1=C(ON=C1NS(=O)(=O)C2=CC=C(C=C2)N)C,Sulfatroxazole,-
810,negative,C[C@H](C(O)=O)C1=CC=C(C=C1)C(=O)C2=CC=CS2,Suprofen,-
811,negative,CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O,Valsartan,-
812,negative,[O-]S([O-])(=O)=O,Sodium Sulfate,P450_HP-Inducer
813,negative,CC1=NC(N)=C(C[N+]2=CSC(CCO)=C2C)C=N1,Thiamine (vit B1),P450_HP-Inducer
814,negative,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Desoxycortone,Steroid_11_beta_hydroxylase-Substrate
815,negative,O=[As]1=[As](=O)O1,Arsenic Trioxide,1B1-Inhibitor
816,negative,OC(=O)CCCC[C@@H]1SC[C@H]2NC(=O)N[C@@H]12,Biotin,1B1-Inducer
817,negative,COC1=C(O)C=C(C=C1)C2=CC(=O)C3=C(O)C=C(O)C=C3O2,Diosmectite,1B1-Inhibitor
818,negative,CCC1(CC)C(=O)NC(=O)N(C)C1=O,Metharbital,1B1-Inducer
819,negative,O[C@H](CBr)[C@@H](O)[C@H](O)[C@H](O)CBr,Mitobronitol,1B1-Inducer
820,negative,CCN(CC)CCC1=NC(=NO1)C2=CC=CC=C2,Oxolamine,1B1-Inducer
821,negative,NC(=O)C1=C(O)C=CC=C1,Salicylamide,1B1-Inhibitor
822,negative,N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O,Tryptophan,1B1-Inducer
823,negative,NC1=NC2=C(C(=O)N1)C(CCC3=CC=C(C=C3)C(=O)N[C@H](CCC(O)=O)C(O)=O)=CN2,Pemetrexed,Proton_coupled_folate_transporter-Substrate
824,negative,CCCC(O)=O,Hydroxybutyric Acid,Monocarboxylate_transporter_1-Substrate
825,negative,C[C@@H](O)C(O)=O,Milchsure,Monocarboxylate_transporter_1-Substrate
826,negative,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1,Niflumic Acid,Monocarboxylate_transporter_1-Inhibitor
827,negative,NC1=CC=C(C=C1)C(=O)NCC(O)=O,Aminohippuric Acid,Solute_carrier_family_22_member_6-Substrate
828,negative,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O,Amoxicillin,Solute_carrier_family_22_member_6-Substrate
829,negative,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C3=CC=CC=C3,Cefaclor,Solute_carrier_family_22_member_6-Inhibitor
830,negative,CC1=NN=C(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)CN4C=NN=N4)C3=O)C(O)=O)S1,Cefazolin,Solute_carrier_family_22_member_6-Substrate
831,negative,NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1,Cidofovir,Solute_carrier_family_22_member_6-Substrate
832,negative,OC1=CC2=C(C=C1)[C@]3(OC(=O)C4=C3C=CC=C4)C5=C(O2)C=C(O)C=C5,Fluorescein,Solute_carrier_family_22_member_6-Substrate
833,negative,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@H]3CC[C@H](N3)C(=O)N(C)C)=C(N2C1=O)C(O)=O,Meropenem,Solute_carrier_family_22_member_6-Substrate
834,negative,COC1=C(C)C2=C(C(O)=C1CC=C(/C)CCC(O)=O)C(=O)OC2,Mycophenolic Acid,Solute_carrier_family_22_member_6-Substrate
835,negative,NC1=NC2=C(N=CN2COCCO)C(=O)N1,Aciclovir,Canalicular_multispecific_organic_anion_transporter_1-Substrate
836,negative,CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O,Benzylpenicillin,Canalicular_multispecific_organic_anion_transporter_1-Inducer
837,negative,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2C(=O)C=C4[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]34C)C(O)=O,Enoxolone,Canalicular_multispecific_organic_anion_transporter_1-Inhibitor
838,negative,CCC1=CC=CC2=C1NC3=C2CCO[C@@]3(CC)CC(O)=O,Etodolac,Canalicular_multispecific_organic_anion_transporter_1-Inhibitor
839,negative,CN[C@H](C)[C@@H]1CC[C@H](N)[C@H](O1)O[C@@H]2[C@@H](N)C[C@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@@H](NC)[C@@H]3O)[C@H]2O,Gentamicin,Canalicular_multispecific_organic_anion_transporter_1-Inducer
840,negative,C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CNC5=CC=CC=C45)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,Octreotide,Canalicular_multispecific_organic_anion_transporter_1-Substrate
841,negative,OC1=CC=C(C=C1)[C@@]2(OC(=O)C3=C2C=CC=C3)C4=CC=C(O)C=C4,Phenolphthalein,Canalicular_multispecific_organic_anion_transporter_1-Substrate
842,negative,O=C1[C@H](CCS(=O)C2=CC=CC=C2)C(=O)N(N1C3=CC=CC=C3)C4=CC=CC=C4,Sulfinpyrazon,Canalicular_multispecific_organic_anion_transporter_1-Substrate
843,negative,CC(C)(C)NC[C@@H](O)COC1=CC=C(NC(=O)N[C@@H]2CCCCC2)C=C1,Talinolol,Canalicular_multispecific_organic_anion_transporter_1-Substrate
844,negative,CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O,Bumetanide,Solute_carrier_family_12_member_2-Inhibitor
845,negative,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Kanamycin,Solute_carrier_family_12_member_2-Inhibitor
846,negative,[Li],Lithium,Solute_carrier_family_12_member_2-Inducer
847,negative,COC1=CC([C@@H](O)[C@@H](C)N)=C(OC)C=C1,Methoxamine,Solute_carrier_family_12_member_2-Inducer
848,negative,O=N[Fe](C#N)(C#N)(C#N)(C#N)C#N,Nitroprusside,Solute_carrier_family_12_member_2-Inhibitor
849,negative,O=O,Oxygen,Solute_carrier_family_12_member_2-Inducer
850,negative,CC[C@H](C)[C@H]1NC(=O)[C@@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,Oxytocin,Solute_carrier_family_12_member_2-Inducer
851,negative,[Cl-].[K+],Potassium Chloride,Solute_carrier_family_12_member_2-Substrate
852,negative,NCC(=O)CCC(O)=O,Aminolevulinic Acid,Solute_carrier_family_15_member_2-Substrate
853,negative,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C2=O)C(O)=O,Cefadroxil,Solute_carrier_family_15_member_2-Substrate
854,negative,CCC(=O)O[C@@H](O[P@@](=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(O)=O)[C@H]3CCCCC3)C(C)C,Fosinopril,Solute_carrier_family_15_member_2-Substrate
855,negative,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=C(C[C@H]2C(O)=O)C=CC=C3,Quinapril,Solute_carrier_family_15_member_2-Inhibitor
856,negative,CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1N=C(N)NC2=O,Valaciclovir,Solute_carrier_family_15_member_2-Substrate
857,negative,CC(C)[C@H](N)C(=O)OC[C@H](CO)OCN1C=NC2=C1NC(N)=NC2=O,Valganciclovir,Solute_carrier_family_15_member_2-Inhibitor
858,negative,CC(C)[C@]1(CC=C)C(=O)NC(=O)NC1=O,Aprobarbital,2B6-Inducer
859,negative,CN[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2,Esketamine,2B6-Substrate
860,negative,CCC(=O)[C@@]1(CCN(C)CC1)C2=CC(O)=CC=C2,Ketobemidone,2B6-Substrate
861,negative,CC1=CC(=O)[C@@H]2C[C@H]1C2(C)C,Levoverbenone,2B6-Substrate
862,negative,CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)OCC2=CC(OC3=CC=CC=C3)=CC=C2,Permethrin,2B6-Inducer
863,negative,CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C,Acetylcarnitine,Solute_carrier_family_22_member_5-Substrate
864,negative,CON=C(/C(=O)N[C@H]1[C@H]2SCC(C[N@+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4,Cefepime,Solute_carrier_family_22_member_5-Inhibitor
865,negative,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@@H]3C[C@H]4[C@@H](CC5=CNC6=CC=CC4=C56)N(C)C3)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C,Ergoloid Mesylates,Solute_carrier_organic_anion_transporter_family_member_2B1-Inhibitor
866,negative,OC([O-])=O,Sodium Bicarbonate,Electroneutral_sodium_bicarbonate_exchanger_1-Substrate
867,negative,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Hydroxyprogesterone,Steroid_21_hydroxylase_21_OHase-Substrate
868,negative,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C(CCC[C@]12C)=CC=C3C[C@H](O)C[C@@H](O)C3=C,Alfacalcidol,Sterol_26_hydroxylase_Sterol_27_hydroxylase_Vitamin_D3_25_hydroxylase_5_beta_cholestane_3_alpha_7_alpha12_alpha_triol_27_hydroxylase-Substrate
869,negative,COC1=CC2=C(C=C1OC)C(CCN3CCN(CC3)C4=CC=CC=C4)=C(C)N2,Oxypertine,Canalicular_multispecific_organic_anion_transporter_2-Inducer
870,negative,NC(=N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]2CSSCCC(=O)N[C@H](CC3=CC=C(O)C=C3)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CC(N)=O)C(=O)N2)C(=O)NCC(N)=O,Desmopressin,Solute_carrier_family_12_member_1-Inducer
871,negative,NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1Cl,Hydrochlorothiazide,Solute_carrier_family_12_member_1-Inducer
872,negative,CC[C@H](C)[C@H]1NC(=O)[C@@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O,Vasopressin,Solute_carrier_family_12_member_1-Inducer
873,negative,NCC1=CC=C(C=C1)C(O)=O,Aminomethylbenzoic Acid,Solute_carrier_family_15_member_1-Inhibitor
874,negative,NC1=NC(=CS1)C(=N/OCC(O)=O)C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O,Cefixime,Solute_carrier_family_15_member_1-Substrate
875,negative,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O,Cefradine,Solute_carrier_family_15_member_1-Inhibitor
876,negative,NC1=NC(=CS1)C(=C/CC(O)=O)C(=O)N[C@H]2[C@@H]3SCC=C(N3C2=O)C(O)=O,Ceftibuten,Solute_carrier_family_15_member_1-Substrate
877,negative,OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O,Didanosine,Solute_carrier_family_15_member_1-Substrate
878,negative,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate
879,negative,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,Oseltamivir,Solute_carrier_family_15_member_1-Substrate
880,negative,O=C(NC1=CC=C2C(=O)C=C(OC2=C1)C3=NN=NN3)C4=CC=C(OCCCCC5=CC=CC=C5)C=C4,Pranlukast,Solute_carrier_family_22_member_11-Inhibitor
881,negative,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2C(CCC[C@]12C)=CC=C3C[C@H](O)CCC3=C,Calcifediol,24A-Substrate
882,negative,CC[C@H](C)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC3=CNC4=C3C=CC=C4)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC6=CC=CC=C6)C(O)=O,Teriparatide,24A-Inhibitor
883,negative,NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N,Amiloride,Solute_carrier_family_22_member_1-Inhibitor
884,negative,NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2,Lamivudine,Solute_carrier_family_22_member_1-Substrate
885,negative,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4,Prazosin,Solute_carrier_family_22_member_1-Inhibitor
886,negative,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,Ganciclovir,Neutral_amino_acid_transporter_B0-Substrate
887,negative,N[C@@H](CCC(N)=O)C(O)=O,Levoglutamide,Neutral_amino_acid_transporter_B0-Substrate
888,negative,CC[C@@]1(C(=O)NC(=O)NC1=O)C2=CCCCC2,Cyclobarbital,HLp2-Inducer
889,negative,CCCC1=NC(C)=C2N1NC(=NC2=O)C3=C(OCC)C=CC(=C3)S(=O)(=O)N4CCN(CC)CC4,Vardenafil,HLp2-Substrate
890,negative,[Br-],Bromides,Solute_carrier_family_22_member_2-Substrate
891,negative,CN1CCN(CC1)[C@@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3,Chlorcyclizine,Multidrug_resistance_associated_protein_1-Substrate
892,negative,OCCN(CCO)C1=NC2=C(N=C(N=C2N3CCCCC3)N(CCO)CCO)C(=N1)N4CCCCC4,Dipyridamole,Multidrug_resistance_associated_protein_1-Inhibitor
893,negative,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)C(=O)CO)C(O)=C3C(=O)C2=CC=C1,Epirubicin,Multidrug_resistance_associated_protein_1-Inducer
894,negative,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@H]4CC[C@]3(O)C2)C6=CC(=O)OC6)[C@H](O)[C@H](O)[C@H]1O,G-strophanthin,Multidrug_resistance_associated_protein_1-Inducer
895,negative,CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1,Chlorpropamide,2C19-Substrate
896,negative,COC1=CC2=C([N-]C(=N2)S(=O)CC3=NC=C(C)C(OC)=C3C)C=C1,Esomeprazole,2C19-Substrate
897,negative,CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4,Etizolam,2C19-Substrate
898,negative,CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3,Fosamprenavir,2C19-Inhibitor
899,negative,O=C(CS(=O)CC1=CC=CO1)NCC=C/COC2=NC=CC(CN3CCCCC3)=C2,Lafutidine,2C19-Inhibitor
900,negative,C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Lynestrenol,2C19-Inducer
901,negative,CN1C(=O)C[C@](C)(C1=O)C2=CC=CC=C2,Mesuximide,2C19-Inhibitor
902,negative,COC1=C(OC)C2=C(C=C1)[C@@H](OC2=O)[C@@H]3N(C)CCC4=CC5=C(OCO5)C(OC)=C34,Noscapine,2C19-Inhibitor
903,negative,COC1=CC(=CC(OC)=C1OC)[C@@H]2[C@H]3[C@@H](COC3=O)CC4=C2C=C5OCOC5=C4,Podophyllotoxin,2C19-Substrate
904,negative,FC1=C(C=CC=C1)C2=NCC(=S)N(CC(F)(F)F)C3=C2C=C(Cl)C=C3,Quazepam,2C19-Substrate
905,negative,CC[C@@]1(CCC(C)C)C(=O)NC(=O)NC1=O,Amobarbital,Coumarin_7_hydroxylase-Inducer
906,negative,[O-]S(=O)(=O)C1=CC=C2NC(C(=O)C2=C1)=C3NC4=CC=C(C=C4C3=O)S([O-])(=O)=O,Indigo Carmine,Coumarin_7_hydroxylase-Inhibitor
907,negative,OCC1=CC=CN=C1,Nicotinyl Alcohol (pyridylcarbinol),Coumarin_7_hydroxylase-Substrate
908,negative,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,Arbekacin,N_acetyltransferase-Substrate
909,negative,COC1=C2C=CC(=O)OC2=CC3=C1C=CO3,Bergapten,N_acetyltransferase-Inhibitor
910,negative,C[N+](C)(C)CCOC(N)=O,Carbachol,N_acetyltransferase-Inhibitor
911,negative,CC(C)NNC(=O)C1=CC=NC=C1,Iproniazide,N_acetyltransferase-Inhibitor
912,negative,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,Lindane,N_acetyltransferase-Inducer
913,negative,CCN[C@@H]1C[C@H](N)[C@@H](O[C@@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O,Netilmicin,N_acetyltransferase-Substrate
914,negative,CNC[C@@H](O)C1=CC=C(O)C=C1,Oxedrine,N_acetyltransferase-Inhibitor
915,negative,NS(=O)(=O)C1=CC=C(C=C1)N2CCCCS2(=O)=O,Sultiame,N_acetyltransferase-Inducer
916,negative,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,Tobramycin,N_acetyltransferase-Substrate
917,negative,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,Adefovir Dipivoxil,2C9-Inhibitor
918,negative,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O,Capecitabine,2C9-Inhibitor
919,negative,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,Clevidipine,2C9-Inhibitor
920,negative,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,Cyclizine,2C9-Inhibitor
921,negative,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O,Diclofenamide,2C9-Inducer
922,negative,CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@@H]2OC(C[C@H]12)=C/CCCC(O)=O,Epoprostenol,2C9-Substrate
923,negative,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C,Mefenamic Acid,2C9-Substrate
924,negative,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O,Nimesulide,2C9-Inhibitor
925,negative,OC(=O)CCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3,Oxaprozin,2C9-Substrate
926,negative,CCOC(=O)CN[C@H]([C@H]1CCCCC1)C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)C=NNO,Ximelagatran,2C9-Substrate
927,negative,CC(O)(CC(O)=O)CC(O)=O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor
928,negative,ClC1=CC(Cl)=C(C=C1)[C@@H](CN2C=CN=C2)OCC3=CSC4=C3C=CC=C4Cl,Sertaconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor
929,negative,CC(C)N1CCN(CC1)C2=CC=C(OC[C@H]3CO[C@](CN4C=NC=N4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2,Terconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor
930,negative,NC(=O)N1C(=O)C(=C(/O)C2=CC=CS2)C3=C1C=CC(Cl)=C3,Tenidap,Electrogenic_sodium_bicarbonate_cotransporter_1-Inhibitor
931,negative,NC1=CC(O)=C(C=C1)C(O)=O,Aminosalicylic Acid,Sodium_coupled_neutral_amino_acid_transporter_3-Substrate
932,negative,[O-]C(=O)C1=C(CS[C@@H]2[C@H](NC(=O)CC3=CC=CS3)C(=O)N12)C[N+]4=CC=CC=C4,Cefaloridine,2C8-Substrate
933,negative,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Mometasone,2C8-Inhibitor
934,negative,OC1=CC=C2C[C@H]3N(CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O)CC=C,Naloxone,2C8-Substrate
935,negative,CCOC(=O)C1=CC=C(N=C1)C#CC2=CC3=C(SCCC3(C)C)C=C2,Tazarotene,2C8-Substrate
936,negative,CC(C)OC(=O)CCCC=CC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC2=CC=CC=C2,Latanoprost,Solute_carrier_organic_anion_transporter_family_member_2A1-Inhibitor
937,negative,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(CC(O)=O)C2=O,Benazepril,Aldosterone_synthase_ALDOS_Aldosterone_synthesizing_enzyme_Steroid_18_hydroxylase-Inhibitor
938,negative,CN(C)CCN1N=NN=C1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)CC4=CSC(N)=N4)C3=O)C(O)=O,Cefotiam,Solute_carrier_family_22_member_8-Substrate
939,negative,NS(=O)(=O)C1=CC2=C(C=C1Cl)N=CNS2(=O)=O,Chlorothiazide,Solute_carrier_family_22_member_8-Substrate
940,negative,OC1=CC=C(C=C1)[C@@]2(OS(=O)(=O)C3=C2C=CC=C3)C4=CC=C(O)C=C4,Phenolsulfonphthalein,Solute_carrier_family_22_member_8-Substrate
941,negative,C[C@@H](CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=CC=C2,Benfluorex,UGT-Inducer
942,negative,C[C@]12CCC(=O)C=C1C=C[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CC[C@@]45CCC(=O)O5,Canrenone,UGT-Inhibitor
943,negative,CC1=NC=C2[C@H](OCC2=C1O)C3=CC=C(Cl)C=C3,Cicletanine,UGT-Substrate
944,negative,CN1CCC(CC1)=C2/C3=C(C=CC=C3)C=CC4=C2C=CC=C4,Cyproheptadin,UGT-Substrate
945,negative,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,Dasatinib,UGT-Inhibitor
946,negative,OC(=O)C1=C(O)C=CC(=C1)C2=C(F)C=C(F)C=C2,Diflunisal,UGT-Substrate
947,negative,NC(=O)N1C2=C(C[C@H](O)C3=C1C=CC=C3)C=CC=C2,Eslicarbazepine,UGT-Substrate
948,negative,CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N,Febuxostat,UGT-Substrate
949,negative,CC1=CC(=O)OC2=C1C=CC(O)=C2,Hymecromone,UGT-Inhibitor
950,negative,[H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O,Mitiglinide,UGT-Substrate
951,negative,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F,Nilotinib,UGT-Inhibitor
952,negative,CO[C@@H]1C[C@@H](O[C@@H](C)[C@H]1O)O[C@H]2[C@H](C)[C@@H](O[C@H]3O[C@@H](C)C[C@H]([C@H]3O)N(C)C)[C@@H](C)C[C@]4(CO4)C(=O)[C@H](C)[C@@H](O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C,Oleandomycin,UGT-Substrate
953,negative,CC1=CC(=C(O)C(C)=C1CC2=NCCN2)C(C)(C)C,Oxymetazoline,UGT-Substrate
954,negative,C[C@H](C(O)=O)C1=CC(Cl)=C(C=C1)N2CC=CC2,Pirprofen,UGT-Substrate
955,negative,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O,Pitavastatin,UGT-Inhibitor
956,negative,[H][C@@](C)(O)[C@]([H])(CC)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@]2([H])CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1,Posaconazole,UGT-Substrate
957,negative,CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Raltegravir,UGT-Substrate
958,negative,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,Sorafenib,UGT-Inhibitor
959,negative,OCCSCCCCCCCCCCSCCO,Tiadenol,UGT-Inducer
960,negative,CCCCC[C@H](O)C=C[C@@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,Alprostadil,Multidrug_resistance_associated_protein_4-Substrate
961,negative,NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F,Gemcitabine,Multidrug_resistance_associated_protein_5-Inducer
962,negative,NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1,Cladribine,ATP_binding_cassette_sub_family_G_member_2-Substrate
963,negative,OC[C@@H](O)COC(=O)C1=C(NC2=C3C=CC(Cl)=CC3=NC=C2)C=CC=C1,Glafenine,ATP_binding_cassette_sub_family_G_member_2-Inhibitor
964,negative,[O-][N+](=O)C1=CC=C(O1)C=NN2CC(=O)NC2=O,Nitrofurantoin,ATP_binding_cassette_sub_family_G_member_2-Substrate
965,negative,CC1=CC2=C(C=C1C)N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)C3=NC(=O)NC(=O)C3=N2,Riboflavin (vit B2),ATP_binding_cassette_sub_family_G_member_2-Substrate
966,negative,CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C3N=C5C=CC(O)=C(CN(C)C)C5=C4)C2=O,Topotecan,ATP_binding_cassette_sub_family_G_member_2-Substrate
967,negative,CC(C)C[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC2=NC=CN2)[C@H](C)O)[C@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O,Secretin,Ileal_sodiumbile_acid_cotransporter-Inducer
968,negative,CC(C)[C@@H](C)C=C[C@@H](C)[C@H]1CC[C@H]2C(CCC[C@]12C)=CC=C3C[C@@H](O)CCC3=C,Ergocalciferol,Arachidonic_acid_epoxygenase-Substrate
969,negative,C[C@H](CC1=CC=C(O)C(O)=C1)[C@@H](C)CC2=CC(O)=C(O)C=C2,Masoprocol,Arachidonic_acid_epoxygenase-Inhibitor
970,negative,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Fingolimod,4F2-Substrate
971,negative,CC1=C(C=CC(C)=C/C=C/C(C)=C/C(O)=O)C(C)(C)CCC1,Alitretinoin,1A2-Inhibitor
972,negative,CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)[C@@H](CO)C3=CC=CC=C3,Atropine,1A2-Inhibitor
973,negative,C[C@H](C(O)=O)C1=CC2=C(OC(=N2)C3=CC=C(Cl)C=C3)C=C1,Benoxaprofen,1A2-Inducer
974,negative,C[C@@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Clobetasol,1A2-Inhibitor
975,negative,COC(=O)NC1=NC2=C(N1)C=CC(SC3=CC=CC=C3)=C2,Fenbendazole,1A2-Inducer
976,negative,CC1=CC(CN2CCN(CC2)[C@@H](C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=CC=C1,Meclozin,1A2-Inhibitor
977,negative,CO[C@@]12[C@H](COC(N)=O)C3=C(N1C[C@@H]4N[C@H]24)C(=O)C(C)=C(N)C3=O,Mitomycin,1A2-Inducer
978,negative,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C3=CC=CC=C3)C=C1,Nitrazepam,1A2-Inducer
979,negative,C[C@@H](N)[C@@H](O)C1=CC=CC=C1,Phenylpropanolamine,1A2-Inhibitor
980,negative,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO,Sorbitol,1A2-Inhibitor
981,negative,CS(=O)(=O)OC[C@H](O)[C@H](O)COS(C)(=O)=O,Treosulfan,1A2-Inhibitor
982,negative,C[C@H](N)[C@H](O)C1=CC(O)=CC=C1,Metaraminol,Sodium_dependent_noradrenaline_transporter-Substrate
983,negative,CC(=O)N[C@H](CS)C(O)=O,Acetylcysteine,Multidrug_resistance_protein_1-Inducer
984,negative,NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O,Cytarabine,Multidrug_resistance_protein_1-Inducer
985,negative,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=C(Cl)C=CC=C4Cl,Dicloxacillin,Multidrug_resistance_protein_1-Substrate
986,negative,OC(=O)CCC(=O)C1=CC=C(C=C1)C2=CC=CC=C2,Fenbufen,Multidrug_resistance_protein_1-Inducer
987,negative,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C=CC6=CC(OC)=C(OC)C(OC)=C6,Rescinnamine,Multidrug_resistance_protein_1-Inducer
988,negative,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,Deferoxamine,1A1-Inhibitor
989,negative,CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C,Mecamylamine,1A1-Inducer
990,negative,COC1=C[C@@H](C)[C@@H]2C[C@@H]3OC(=O)C[C@H]4C(C)=C(OC)C(=O)[C@@H]([C@]34C)[C@@]2(C)C1=O,Quassia,1A1-Inhibitor
991,negative,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,Retigabine,1A1-Substrate
992,negative,N[C@@H]1CONC1=O,Cycloserine,Proton_coupled_amino_acid_transporter_1-Substrate
993,negative,N[C@@H](CC1=CNC2=C1C=C(O)C=C2)C(O)=O,Oxitriptan,Proton_coupled_amino_acid_transporter_1-Inhibitor
994,negative,N[C@@H](CCC(O)=O)C=C,Vigabatrin,Proton_coupled_amino_acid_transporter_1-Substrate
995,negative,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)[C@H]3CCCO3,Alfuzosin,3A4-Substrate
996,negative,C[C@@]12CC[C@@H]3[C@H](CCC4=CCCC[C@@H]34)[C@@H]1CC[C@@]2(O)CC=C,Allylestrenol,3A4-Substrate
997,negative,CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1,Atenolol,3A4-Substrate
998,negative,N.N.O=C1O[Pt]OC(=O)C12CCC2,Carboplatin,3A4-Inducer
999,negative,CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@H](O)CCN,Caspofungin,3A4-Inhibitor
1000,negative,CN(C)CCC=C1/C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2,Chlorprothixene,3A4-Substrate
1001,negative,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@@H]3[C@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@H]4[C@@H](O)C[C@@]23C)[C@H]6CCCCC6,Ciclesonide,3A4-Substrate
1002,negative,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]2[C@@H](O[C@@H](C)[C@]2(O)CO)O[C@@H]3[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]3NC(N)=N,Dihydrostreptomycin,3A4-Substrate
1003,negative,C[C@@H](CN1C2=C(SC3=CC=C(C=C13)S(=O)(=O)N(C)C)C=CC=C2)N(C)C,Dimetotiazine,3A4-Inhibitor
1004,negative,ClC1=CC2=C(C=C1)N3C=NN=C3CN=C2C4=CC=CC=C4,Estazolam,3A4-Substrate
1005,negative,C[C@@]12CC[C@@H]3[C@H](CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)[C@@H]1CC[C@@H]2O,Estramustine,3A4-Substrate
1006,negative,CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O,Famciclovir,3A4-Substrate
1007,negative,C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC4=CC(O)=CC=C34)[C@@H]1CC[C@@H]2O,Fulvestrant,3A4-Substrate
1008,negative,NC(=N)NCCN1CCCCCCC1,Guanethidine,3A4-Inducer
1009,negative,[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Hydrocortisone Aceponate,3A4-Substrate
1010,negative,OC1=CC=C(O)C=C1,Hydroquinone,3A4-Substrate
1011,negative,O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O,Isosorbide Mononitrate,3A4-Substrate
1012,negative,CC1=C(C=CC(C)=CC=CC(C)=C/C(O)=O)C(C)(C)CCC1,Isotretinoin,3A4-Substrate
1013,negative,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1,Ivabradine,3A4-Substrate
1014,negative,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,Levothyroxine Sodium,3A4-Substrate
1015,negative,CC(=O)[C@@]1(C)CC[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@@]12C,Medrogestone,3A4-Substrate
1016,negative,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,Metandienone,3A4-Substrate
1017,negative,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O,Methylprednisolone Aceponate,3A4-Inducer
1018,negative,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)CC=CC=C[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(OC(C)=O)[C@@H](OC(=O)CC)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC,Miocamycin,3A4-Inhibitor
1019,negative,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,Pazopanib,3A4-Inhibitor
1020,negative,C[C@H](COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2,Phenoxybenzamine,3A4-Substrate
1021,negative,CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O,Phenoxymethylpenicillin,3A4-Inducer
1022,negative,[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC,Pimecrolimus,3A4-Substrate
1023,negative,ClC1=CC2=C(C=C1)N(C[C@H]3CC3)C(=O)CN=C2C4=CC=CC=C4,Prazepam,3A4-Substrate
1024,negative,CCCCC(C(=O)O[C@H]1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3,Propiverine,3A4-Inhibitor
1025,negative,CN(C)C(=O)OC1=C[N+](C)=CC=C1,Pyridostigmine,3A4-Inducer
1026,negative,CC[C@H]1NC(=O)[C@@H](NC(=O)C2=NC=CC=C2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@H]3CC(=O)[C@H](CS[C@@H]4CN5CC[C@@H]4CC5)CN3C(=O)[C@H](CC6=CC=C(C=C6)N(C)C)N(C)C(=O)[C@@H]7CCCN7C1=O)C8=CC=CC=C8,Quinupristin/dalfopristin,3A4-Inhibitor
1027,negative,CO[C@H]1C=CO[C@@]2(C)OC3=C(C2=O)C4=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C5=C4N=C6C=C(C)C=CN56,Rifaximin,3A4-Inducer
1028,negative,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1,Rufinamide,3A4-Inducer
1029,negative,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Saxagliptin,3A4-Substrate
1030,negative,[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,Sodium Edetate,3A4-Substrate
1031,negative,CO[C@H]1[C@H](O)CC(=O)O[C@H](C)CC=CC=C[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]3O[C@H](C)[C@@H](O[C@H]4C[C@@](C)(O)[C@@H](O)[C@H](C)O4)[C@@H]([C@H]3O)N(C)C,Spiramycin,3A4-Substrate
1032,negative,CC(C)=C/[C@@H]1[C@@H](C(=O)OCN2C(=O)C3=C(CCCC3)C2=O)C1(C)C,Tetramethrin,3A4-Inducer
1033,negative,CC[C@@H]1C(C)=NN=C(C2=CC(OC)=C(OC)C=C2)C3=C1C=C(OC)C(OC)=C3,Tofisopam,3A4-Inhibitor
1034,negative,CN1C(CC(O)=O)=CC(C)=C1C(=O)C2=CC=C(Cl)C=C2,Zomepirac,3A4-Substrate
1035,negative,CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OC[C@@H](O)CNC(C)(C)C)C=C1,Celiprolol,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate
1036,negative,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=C/CCCC(O)=O,Unoproston,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate
1037,positive,Cl.[Cl-].C[n+]1c2cc(N)ccc2cc3ccc(N)cc13.Nc4ccc5cc6ccc(N)cc6nc5c4,Acriflavinium Chloride,1A2-Substrate
1038,positive,CCCSC1=CC2=C(NC(NC(=O)OC)=N2)C=C1,Albendazole,1A2-Substrate
1039,positive,CN1C2=C(C(=O)N(CC2)CC3=C(C)N=CN3)C4=C1C=CC=C4,Alosetron,1A2-Substrate
1040,positive,CN(C)C1=C(C)N(C)N(C2=CC=CC=C2)C1=O,Aminophenazone,1A2-Substrate
1041,positive,CN1C(=O)N(C)C2=C(NC=N2)C1=O,Aminophylline,1A2-Substrate
1042,positive,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C3=CC=CC=C3O1,Amiodarone,1A2-Substrate
1043,positive,CN(C)CCC=C1/C2=C(CCC3=C1C=CC=C3)C=CC=C2,Amitriptyline,1A2-Substrate
1044,positive,ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl,Anagrelide,1A2-Substrate
1045,positive,C[C@@H](O[C@@H]1OCCN(CC2=NC(=O)NN2)[C@@H]1C3=CC=C(F)C=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F,Aprepitant,1A2-Substrate
1046,positive,CN1CCC[C@@H](CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O,Azelastine,1A2-Substrate
1047,positive,CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3,Benzydamine,1A2-Substrate
1048,positive,CC(C)NC[C@H](O)COC1=CC=C(CCOC[C@H]2CC2)C=C1,Betaxolol,1A2-Substrate
1049,positive,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)C2=CN=CC=N2)B(O)O,Bortezomib,1A2-Substrate
1050,positive,BrC1=CC2=C(NC(=O)CN=C2C3=CC=CC=N3)C=C1,Bromazepam,1A2-Substrate
1051,positive,CCCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C,Bupivacaine,1A2-Substrate
1052,positive,C[C@H](NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,Bupropion,1A2-Substrate
1053,positive,CN1C=NC2=C1C(=O)N(C)C(=O)N2C,Caffeine,1A2-Substrate
1054,positive,COC1=C(O)C=CC(CNC(=O)CCCCC=CC(C)C)=C1,Capsaicin,1A2-Substrate
1055,positive,NC(=O)N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3,Carbamazepine,1A2-Substrate
1056,positive,ClCCNC(=O)N(CCCl)N=O,Carmustine,1A2-Substrate
1057,positive,COC1=C(OCCNC[C@@H](O)COC2=CC=CC3=C2C4=CC=CC=C4N3)C=CC=C1,Carvedilol,1A2-Substrate
1058,positive,COC1=CC2=C(C=CN=C2C=C1)[C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C,Chinin,1A2-Substrate
1059,positive,CN(C)CCCN1C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2,Chlorpromazine,1A2-Substrate
1060,positive,OC1=NC2=C(O1)C=CC(Cl)=C2,Chlorzoxazone,1A2-Substrate
1061,positive,O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2,Cilostazol,1A2-Substrate
1062,positive,C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12,Cinacalcet,1A2-Substrate
1063,positive,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,Cinnarizin,1A2-Substrate
1064,positive,CO[C@@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C3=C(OC)C=C(N)C(Cl)=C3,Cisapride,1A2-Substrate
1065,positive,CC(C)(C)NC[C@H](O)C1=CC(Cl)=C(N)C(Cl)=C1,Clenbuterol,1A2-Substrate
1066,positive,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=C(Cl)C=C13,Clomipramine,1A2-Substrate
1067,positive,COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3,Clopidogrel,1A2-Substrate
1068,positive,CN1CCN(CC1)C2=NC3=C(NC4=C2C=CC=C4)C=CC(Cl)=C3,Clozapine,1A2-Substrate
1069,positive,C[C@H](CN(C)C)CN1C2=C(SC3=C1C=C(C=C3)C#N)C=CC=C2,Cyamemazine,1A2-Substrate
1070,positive,CN(C)CCC=C1/C2=C(C=CC=C2)C=CC3=C1C=CC=C3,Cyclobenzaprine,1A2-Substrate
1071,positive,CC1(C)[C@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@H](C#N)C2=CC(OC3=CC=CC=C3)=CC=C2,Cypermethrin,1A2-Substrate
1072,positive,CN(C)N=NC1=C(N=CN1)C(N)=O,Dacarbazine,1A2-Substrate
1073,positive,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(C)=O)C(O)=C3C(=O)C2=CC=C1,Daunorubicin,1A2-Substrate
1074,positive,CN(C)CCO,Deanol,1A2-Substrate
1075,positive,CC1(C)[C@@H](C=C(/Br)Br)[C@H]1C(=O)O[C@H](C#N)C2=CC(OC3=CC=CC=C3)=CC=C2,Decamethrin,1A2-Substrate
1076,positive,CNCCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,Desipramine,1A2-Substrate
1077,positive,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F,Dexfenfluramine,1A2-Substrate
1078,positive,CN1C(=O)CN=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3,Diazepam,1A2-Substrate
1079,positive,OC(=O)CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl,Diclofenac,1A2-Substrate
1080,positive,CCN(CC)C(=O)C1=CC=CC(C)=C1,Diethyltoluamide,1A2-Substrate
1081,positive,NNC1=NN=C(NN)C2=C1C=CC=C2,Dihydralazine,1A2-Substrate
1082,positive,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,Dinoprostone,1A2-Substrate
1083,positive,CCN(CC)C(=S)SSC(=S)N(CC)CC,Disulfiram,1A2-Substrate
1084,positive,ClC1=CC2=C(C=C1)N([C@@H]3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2,Domperidone,1A2-Substrate
1085,positive,NCCC1=CC(O)=C(O)C=C1,Dopamine,1A2-Substrate
1086,positive,CN(C)CCC=C1/C2=C(COC3=C1C=CC=C3)C=CC=C2,Doxepin,1A2-Substrate
1087,positive,CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,Duloxetine,1A2-Substrate
1088,positive,CN1C[C@@H](C=C2[C@H]1CC3=CNC4=C3C2=CC=C4)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O,Ergotamine,1A2-Substrate
1089,positive,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,Erlotinib,1A2-Substrate
1090,positive,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]3O[C@@H](C)C[C@H]([C@@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin,1A2-Substrate
1091,positive,C[C@@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@H]2O,Estradiol,1A2-Substrate
1092,positive,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O,Estrone,1A2-Substrate
1093,positive,CCO,Ethanol,1A2-Substrate
1094,positive,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C,Ethinylestradiol,1A2-Substrate
1095,positive,COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)C6=CC7=C(OCO7)C=C26,Etoposide,1A2-Substrate
1096,positive,FC(F)(F)COC1=CC(C(=O)NC[C@@H]2CCCCN2)=C(OCC(F)(F)F)C=C1,Flecainide,1A2-Substrate
1097,positive,FC1=CC=C(C=C1)C(N2CCN(CC2)CC=CC3=CC=CC=C3)C4=CC=C(F)C=C4,Flunarizine,1A2-Substrate
1098,positive,CN1C(=O)CN=C(C2=C(F)C=CC=C2)C3=C1C=CC(=C3)[N+]([O-])=O,Flunitrazepam,1A2-Substrate
1099,positive,FC1=CNC(=O)NC1=O,Fluorouracil,1A2-Substrate
1100,positive,CNCC[C@@H](OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2,Fluoxetine,1A2-Substrate
1101,positive,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,Flutamide,1A2-Substrate
1102,positive,COCCCCC(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F,Fluvoxamine,1A2-Substrate
1103,positive,CN[C@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(N)=O,Frovatriptan,1A2-Substrate
1104,positive,CN1[C@H]2CCC[C@@H]1C[C@H](C2)NC(=O)C3=NN(C)C4=C3C=CC=C4,Granisetron,1A2-Substrate
1105,positive,COC1=CC(OC)=C2C(=O)[C@]3(OC2=C1Cl)[C@H](C)CC(=O)C=C3OC,Griseofulvin,1A2-Substrate
1106,positive,CC(C)C1=CC2=C(C)C=CC2=C(C)C=C1,Guajazulen,1A2-Substrate
1107,positive,O[C@@]1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Cl)C=C3,Haloperidol,1A2-Substrate
1108,positive,CN1C(O)=NC(=O)[C@@](C)(C2=CCCCC2)C1=O,Hexobarbital,1A2-Substrate
1109,positive,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,Idebenone,1A2-Substrate
1110,positive,CN1CCN(CC1)CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC=CC(=N4)C5=CC=CN=C5)=C(C)C=C3,Imatinib,1A2-Substrate
1111,positive,CN(C)CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,Imipramine,1A2-Substrate
1112,positive,C[N+](C)([O-])CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,Imipramine Oxide,1A2-Substrate
1113,positive,CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12,Imiquimod,1A2-Substrate
1114,positive,CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3,Ipriflavone,1A2-Substrate
1115,positive,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C,Lidocain,1A2-Substrate
1116,positive,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCN[C@H](C)C3)C(F)=C12,Lomefloxacin,1A2-Substrate
1117,positive,CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1,Lumiracoxib,1A2-Substrate
1118,positive,CCOC(=O)C[C@H](SP(=S)(OC)OC)C(=O)OCC,Malathion,1A2-Substrate
1119,positive,CNCCC[C@@]12CC[C@@H](C3=C1C=CC=C3)C4=C2C=CC=C4,Maprotiline,1A2-Substrate
1120,positive,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1,Melatonin,1A2-Substrate
1121,positive,CC1=CC(=O)C2=C(C=CC=C2)C1=O,Menadione,1A2-Substrate
1122,positive,CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Methadone,1A2-Substrate
1123,positive,COC(F)(F)C(Cl)Cl,Methoxyflurane,1A2-Substrate
1124,positive,C[C@@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O,Methyldopa (levorotatory),1A2-Substrate
1125,positive,C[C@H](N)COC1=C(C)C=CC=C1C,Mexiletine,1A2-Substrate
1126,positive,CN1CCN2[C@H](C1)C3=C(CC4=C2C=CC=C4)C=CC=C3,Mianserin,1A2-Substrate
1127,positive,CN1CCN2[C@H](C1)C3=C(CC4=C2N=CC=C4)C=CC=C3,Mirtazapine,1A2-Substrate
1128,positive,COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2,Nabumetone,1A2-Substrate
1129,positive,COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O,Naproxen,1A2-Substrate
1130,positive,CN1CCC[C@H]1C2=CC=CN=C2,Nicotine,1A2-Substrate
1131,positive,CNCCC=C1/C2=C(CCC3=C1C=CC=C3)C=CC=C2,Nortriptyline,1A2-Substrate
1132,positive,CN1CCN(CC1)C2=NC3=C(NC4=C2C=C(C)S4)C=CC=C3,Olanzapine,1A2-Substrate
1133,positive,COC1=CC2=C(NC(=N2)S(=O)CC3=C(C)C(OC)=C(C)C=N3)C=C1,Omeprazole,1A2-Substrate
1134,positive,CN1C2=C(C(=O)[C@H](CC2)CN3C=CN=C3C)C4=CC=CC=C14,Ondansetron,1A2-Substrate
1135,positive,N[C@@H]1CCCC[C@H]1N,Oxaliplatin,1A2-Substrate
1136,positive,[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2,Palonosetron,1A2-Substrate
1137,positive,COC1=C(OC)C(CS(=O)C2=NC3=CC(OC(F)F)=CC=C3N2)=NC=C1,Pantoprazole,1A2-Substrate
1138,positive,CC(=O)NC1=CC=C(O)C=C1,Paracetamol,1A2-Substrate
1139,positive,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O,Paraoxon,1A2-Substrate
1140,positive,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1,Pentamidine Isethionate,1A2-Substrate
1141,positive,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,Pentoxifylline,1A2-Substrate
1142,positive,CN1CCN(CCCN2C3=C(SC4=C2C=CC=C4)C=CC=C3)CC1,Perazine,1A2-Substrate
1143,positive,OCCN1CCN(CCCN2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1,Perphenazine,1A2-Substrate
1144,positive,CCOC1=CC=C(NC(C)=O)C=C1,Phenacetin,1A2-Substrate
1145,positive,CN1N(C(=O)C=C1C)C2=CC=CC=C2,Phenazone,1A2-Substrate
1146,positive,FC1=CC=C(C=C1)C(CCCN2CC[C@@H](CC2)N3C(=O)NC4=C3C=CC=C4)C5=CC=C(F)C=C5,Pimozide,1A2-Substrate
1147,positive,CC1=CN(C(=O)C=C1)C1=CC=CC=C1,Pirfenidone,1A2-Substrate
1148,positive,O=C1CN(C[C@H]2N1CCC3=C2C=CC=C3)C(=O)[C@H]4CCCCC4,Praziquantel,1A2-Substrate
1149,positive,COC1=CC(N[C@H](C)CCCN)=C2N=CC=CC2=C1,Primaquine,1A2-Substrate
1150,positive,CNNCC1=CC=C(C=C1)C(=O)NC(C)C,Procarbazine,1A2-Substrate
1151,positive,CC(=O)[C@@H]1CC[C@@H]2[C@H]3CCC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,Progesterone,1A2-Substrate
1152,positive,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1,Proguanil,1A2-Substrate
1153,positive,CN(C)CCCN1C2=C(SC3=C1C=CC=C3)C=CC=C2,Promazine,1A2-Substrate
1154,positive,CCCNC[C@@H](O)COC1=C(C=CC=C1)C(=O)CCC2=CC=CC=C2,Propafenone,1A2-Substrate
1155,positive,CC(C)C1=CC=CC(C(C)C)=C1O,Propofol,1A2-Substrate
1156,positive,CC(C)NC[C@@H](O)COC1=C2C=CC=CC2=CC=C1,Propranolol,1A2-Substrate
1157,positive,NC(=O)C1=CN=CC=N1,Pyrazinamide,1A2-Substrate
1158,positive,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,Ranitidine,1A2-Substrate
1159,positive,C#CCNC1CCC2=CC=CC=C12,Rasagiline,1A2-Substrate
1160,positive,CC(=C/CO)C=CC=C(C)C=CC1=C(C)CCCC1(C)C,Retinol (vit A),1A2-Substrate
1161,positive,CO[C@H]1C=CO[C@@]2(C)OC3=C(C)C(O)=C4C(=O)C(NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C5N[C@]6(CCN(CC6)CC(C)C)N=C5C4=C3C2=O,Rifabutin,1A2-Substrate
1162,positive,CO[C@H]1C=CO[C@@]2(C)OC3=C(C2=O)C4=C(O)C(C=NN5CCN(C)CC5)=C(NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C4C(O)=C3C,Rifampicin,1A2-Substrate
1163,positive,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2,Riluzole,1A2-Substrate
1164,positive,CC(C)[C@@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,Ritonavir,1A2-Substrate
1165,positive,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3,Rofecoxib,1A2-Substrate
1166,positive,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2,Ropinirole,1A2-Substrate
1167,positive,CCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C,Ropivacaine,1A2-Substrate
1168,positive,C[C@H](CC1=CC=CC=C1)N(C)CC#C,Selegiline,1A2-Substrate
1169,positive,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C3=C1C=CC=C3,Sertraline,1A2-Substrate
1170,positive,NC1=C2CCCCC2=NC3=C1C=CC=C3,Tacrine,1A2-Substrate
1171,positive,FC1=CN([C@H]2CCCO2)C(=O)NC1=O,Tegafur,1A2-Substrate
1172,positive,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCN4C=NC(=C4)C5=CC=CN=C5)C(=O)O[C@]13C)OC,Telithromycin,1A2-Substrate
1173,positive,C[C@@H]1CN(CCN1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4=C(F)C=C(F)C=C4)C(O)=O,Temafloxacin,1A2-Substrate
1174,positive,CN(CC=CC#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1,Terbinafine,1A2-Substrate
1175,positive,CN1C=NC2=C1C(=O)NC(=O)N2C,Theobromine,1A2-Substrate
1176,positive,CSC1=CC2=C(SC3=C(C=CC=C3)N2CC[C@@H]4CCCCN4C)C=C1,Thioridazine,1A2-Substrate
1177,positive,N1C2=C(C=CC=C2)N=C1C3=CSC=N3,Tiabendazole,1A2-Substrate
1178,positive,CN1CCN(CCC=C2C3=C(SC4=C2C=C(C=C4)S(=O)(=O)N(C)C)C=CC=C3)CC1,Tiotixene,1A2-Substrate
1179,positive,ClC1=C(NC2=NCCN2)C3=NSN=C3C=C1,Tizanidine,1A2-Substrate
1180,positive,C[C@H](CN1CCCCC1)C(=O)C2=CC=C(C)C=C2,Tolperisone,1A2-Substrate
1181,positive,CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3,Toremifene,1A2-Substrate
1182,positive,NC1=NC2=C(N=C(C3=CC=CC=C3)C(N)=N2)C(N)=N1,Triamterene,1A2-Substrate
1183,positive,ClC=C(Cl)Cl,Trichloroethylene,1A2-Substrate
1184,positive,CN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1,Trifluoperazine,1A2-Substrate
1185,positive,COC1=C(OC)C=C(CCN(C)CCC[C@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,Verapamil,1A2-Substrate
1186,positive,CC[C@@]12CCCN3CCC4=C([C@H]13)N(C5=C4C=CC=C5)[C@](O)(C2)C(=O)OC,Vincamine,1A2-Substrate
1187,positive,CC(=O)C[C@H](C1=CC=CC=C1)C2=C(O)C3=C(OC2=O)C=CC=C3,Warfarin,1A2-Substrate
1188,positive,ClC1=CC2=C(CC(=O)N2)C=C1CCN3CCN(CC3)C4=NSC5=CC=CC=C45,Ziprasidone,1A2-Substrate
1189,positive,CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2,Zolmitriptan,1A2-Substrate
1190,positive,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C3=CC=C(C)C=C3,Zolpidem,1A2-Substrate
1191,positive,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(Cl)C=C3,Zotepine,1A2-Substrate
